Coptidis Rhizoma: a comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology

Jin Wang*, Lin Wang*, Guan-Hua Lou, Hai-Rong Zeng, Ju Hu, Qin-Wan Huang, Wei Peng and Xiang-Bo Yang

*College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China; †Ya'an Xun Kang Pharmaceutical Co., Ltd, Ya'an, China

ABSTRACT
Context: Coptidis rhizome (CR), also known as Huanglian in Chinese, is the rhizome of Coptis chinensis Franch., C. deltoidea C.Y. Cheng et Hsiao, or C. teeta Wall (Ranunculaceae). It has been widely used to treat bacillary dysentery, diabetes, pertussis, sore throat, aphtha, and eczema in China.

Objectives: The present paper reviews the latest advances of CR, focusing on the botany, phytochemistry, traditional usages, pharmacokinetics, pharmacology and toxicology of CR and its future perspectives.

Methods: Studies from 1985 to 2018 were reviewed from books; PhD. and MSc. dissertations; the state and local drug standards; PubMed; CNKI; Scopus; the Web of Science; and Google Scholar using the keywords Coptis, Coptidis Rhizoma, Huanglian, and goldthread.

Results: Currently, 128 chemical constituents have been isolated and identified from CR. Alkaloids are the characteristic components, together with organic acids, coumarins, phenylpropanoids and quinones. The extracts/compounds isolated from CR cover a wide pharmacological spectrum, including antibacterial, antivirus, antifungal, antidiabetic, anticancer and cardioprotective effects. Berberine is the most important active constituent and the primary toxic component of CR.

Conclusions: As an important herbal medicine in Chinese medicine, CR has the potential to treat various diseases. However, further research should be undertaken to investigate the clinical effects, toxic constituents, target organs and pharmacokinetics, and to establish criteria for quality control, for CR and its related medications. In addition, the active constituents, other than alkaloids, in both raw and processed products of CR should be investigated.

Introduction
Coptidis rhizome (CR), also known as Huanglian in Chinese, is the rhizome of Coptis chinensis Franch. (Weilian in Chinese), C. deltoidea C.Y. Cheng et Hsiao (Yalian in Chinese), or C. teeta Wall. (Yunlian in Chinese) (Ranunculaceae) (Chinese Pharmacopoeia Commission 2015). Moreover, C. japonica Makino and its variants are also used in Japan (Cho et al. 2001). Large quantities of CR are consumed in Asian countries, such as China, Japan, Malaysia, Singapore and India, but only a small amount is used in European countries (Kong et al. 2013).

CR has been used to treat various inflammatory disorders and related diseases for a thousand years, and has functions of clearing heat, drying dampness and detoxification according to the traditional Chinese Medicinal theory. The medicinal use of this plant was first listed in Shenmong's Classic of Materia Medica in China, which was written during the Han Dynasty. More than 32,000 Chinese Medical formulas mention CR, usually in the form of a powder, pill, decoction or tablet (Wu et al. 2015). It is often utilized to treat diarrhoea, vomiting, abdominal fullness, jaundice, high fever coma, toothache, diabetes and eczema. Modern studies have demonstrated that CR has wide pharmacological activities, including antibacterial, antifungal, antiviral, antihepatic steatosis, anti-atherosclerosis, antimyocardial ischaemia/reperfusion injury, antidiabetic, antiarrhythmia, antihypertension, anti-inflammation, antioxidation and antitumour effects (Ma and Ma 2013; Wang 2016; Dan et al. 2017; Liu D et al. 2017). Currently, over 120 chemical components have been isolated and identified from CR. Apart from its main composition of alkaloids, it also contains organic acids, lignans, flavones, volatile oils, etc. (Yoshikawa et al. 1997a, 1997b; Wang et al. 2014; Chen et al. 2016). The present review provides the overview of CR from 1985 to 2018 in terms of its botany, phytochemistry, traditional usages, pharmacology, pharmacokinetics and toxicology. We also offer some perspectives about the future research into this herbal medicine.

Traditional usages
The rhizome is the main medicinal part of CR, and it is processed by 28 methods before clinical use, some of which are taken from ancient Chinese medicines books (Table 1). From these methods, we observed that CR processing has changed from simple to complex and then from complex to simple (Mei 2008). Nowadays, CR is commonly processed with wine, Zingiber...
officinalis Rosc. (Zingiberaceae) juice, and Evodia rutaecarpa (Juss.) Benth. (Rutaceae) to exert different functions including treating insomnia, sore mouth, red and swelling eyes, preventing vomiting, expelling phlegm and curing diarrhoea (Lei and Dun 2002; Lu 2004; Li 2013; Chinese Pharmacopoeia Commission 2015). The medicinal value of CR is worth affirming. Relevant statistics show that in 13 prescriptions before the Song Dynasty, more than 32,000 Chinese Medical formulae mentioned CR. Currently, CR is commonly used as a main traditional Chinese medicine (TCM) to treat respiratory diseases (including tuberculous empyema, whooping cough, and pulmonary candidiasis caused by pneumonia), digestive diseases (including diarrhoea, chronic colitis and upper gastrointestinal infection), paediatric diseases (including hyperthermia of infantile external sensation, dyspepsia and urticaria), dermatological diseases (including acne, psoriasis, dermatitis and tinea pedis), and nervous system diseases (Wu et al. 2015). CR has been employed in the form of powders, pills or decoctions (Table 2).

**Botany**

*Coptis chinensis* (Figure 1(A)) is a perennial herb with yellow, branched rhizomes. The leaves are slightly leathery, with three lobes (Xiao 2002). The scapes are 12–25 cm high. In addition, 3–8 flowers are clustered into a dichasium or pleiochasm. The five sepal, 9–12.5 mm in length, 2–3 mm in width, are greenish yellow and oblong ovate. There are approximately 20 stamens with 8–12 carpels, which are slightly curved outside. The 6–12 follicles are 6–8 mm in length with a thin handle. There are 7–8 brown, oblong seeds that are 2 mm long and 8 mm wide. Flowering occurs from February to March, and the fruit is commonly harvested from April to June. It is distributed in Sichuan, Guizhou, Hunan, Hubei, and southern Shaanxi in China. This plant grows in mountain forests or valleys at an altitude of approximately 500–2000 m (Flora 2004).

*C. deltoidea* (Figure 1(B)) is also a perennial herb with unbranched or few branched yellow rhizomes. The 3–11 leaves are oval and slightly leathery, are 16 cm long and 15 cm wide and are finely divided into three parts. The one or two scapes are slightly longer than the leaves. The plant produces 4–8 flowers, which are clustered into a blue-green inflorescence. Sepals are yellow-green, narrow ovoid, 8–12.5 mm long, and 2–2.5 mm wide. There are approximately 20 stamens, which are about half the length of the petals. The anther is yellow, and the filament is narrowly linear. The flowering period is March and April and the fruit are harvested from April to June. It is native to the areas of Emei and Hongya in Sichuan province. This plant grows in mountain forests with an altitude approximately 1600–2200 m (Flora 2004).

*C. teeta* (Figure 1(C)) is an often used as a folk medicine in Yunnan Province of China. It is a perennial herb with yellow rhizomes yellow, dense internodes and mostly fibrous roots. The blade comprises oval-shaped triangles that are 6–12 cm long and 5–9 cm wide, with a triple fissure. *C. teeta* has one or two scapes and is 15–25 cm high during the fruiting period. It has a blue-green inflorescence with 3–5 flowers. The yellow-green, oval calyx is 7.5–8 mm long and 2.5–3 mm wide. The anther is about 0.8 mm long and filament is 2–2.5 mm long. *C. teeta* is commonly distributed in Yunnan and Tibet provinces of China, and in Burma. *C. teeta* commonly grows in the shade of cold and damp mountainous areas with an altitude of approximately 1500–2300 m (Flora 2004).

The major morphological differences among the rhizomes of these three plants is that Weilian is curved, branched, clustered, and shaped like chicken’s feet; Yalian is less branched and cylindrical; while Yunlian is the smallest and is shaped like a scorpion’s tail. In this review, we will mainly discuss the advances in research into CR from *Coptis chinensis*, which is the most common source for CR.

**Phytochemistry**

The first investigation concerning the chemical components of CR, which succeeded in isolating berberine (1), was reported in 1862 from *C. teeta* (Perrins 1862). To date, over 100 chemical constituents have been isolated and identified. Alkaloids are the most abundant among these chemical components and are considered as the main active ingredients of CR. Besides alkaloids, CR contains organic acids, coumarins, phenylpropanoids, quinones and other chemical components. In this section, the structures of the main compounds of CR are described and drawn (Table 3; Figures 2–10).
| Preparation                  | Main compositions                                                                 | Traditional and clinical uses                                                                 | References                                      |
|------------------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------|
| An Gong Niu Huang Pills      | Coptidis Rhizoma, Bovis Calculus, Condensed powder of Bubali Corum, Moschusmus or Artificial Moschusmus, Marganta, Cinnabaris, Realgar, Scutellariae Radix, Gardeniae Fructus, Curcumae Radix, Syntheticum Borneolium | Curing febrile convulsions, delirious, and gibberish                                           | (Chinese Pharmacopoeia Commission 2015)         |
| Dang Gui Long Hui Pills      | Coptidis Rhizoma, Angelicae Sinensis Radix, Gentianae Radix et Rhizoma, Rhei Radix et Rhizoma, Scutellariae Radix, Phellodendri Chinesis Cortex, Aloe, Ineigo Naturalis, Gardeniae Fructus, Aucklandiae Radix, Artificial Moschusmus | Curing dizziness, tinnitus, deafness, rib pain, abdominal distension pain and constipation    |                                                |
| Fu Fang Qing Dai Pill        | Coptidis Rhizoma, Cnidii Fructus, Sophorae Flavescentis Radix, Pseudolaricis Radix, Catechu, Alumen  | Treating mycotic vaginitis, trichomonas vaginitis, and nonspecific vaginitis                      |                                                |
| Huang Lian Shang Qing Pills  | Coptidis Rhizoma, Gardeniae Fructus, Forsythiae Fructus, Vitisii Fructus, Saposhnikoviae Radix, Schizonepetae Spica, Angelicae Dahuricae Radix, Scutellariae Radix, Rhei Radix et Rhizoma, Chrysantheni Flos, Mentheae Haplocalyx Herba, Phellodendri Chinesis Cortex, Platycodonis Radix, Chuanxiong Rhizoma | Treating dizziness, tooth pain, tongue sores, sore throat, ear pain tinnitus and constipation |                                                |
| Huang Lian Yang Gan Pills    | Coptidis Rhizoma, Rhizoma Picrohiza, Scutellariae Radix, Phellodendri Chinesis Cortex, Gentianae Radix et Rhizoma, Bupleuri Radix, Citri Reticulatae Pericarpium Viride, Equiseti Hiemalis Herba, Buddlejae Flos, Leonuri Fructus, Cassiae Semen, Haliotidis Concha | Treating red sore, eye, blurred vision                                                         |                                                |
| Kai Guang Fu Ming Pills      | Coptidis Rhizoma, Gardeniae Fructus, Phellodendri Chinesis Cortex, Scutellariae Radix, Rhei Radix et Rhizoma, Saposhnikoviae Radix, Chrysantheni Flos, Gentianae Radix et Rhizoma, Scrophulariae Radix, Paeoniae Radix Rubra, Alismatis Rhizoma, Rehmanniae Radix | Clearing heat and improving eyesight                                                           |                                                |
| Mu Xiang Bing Lang Pills     | Coptidis Rhizoma, Aucklandiae Radix, Arecae Semen, Aurantii Fructus, Citri Reticulatae Pericarpium, Citri Reticulatae Pericarpium Viride, Cypere Rhizoma, Spargani Rhizoma, Curcumae Rhizoma, Phellodendri Chinesis Cortex, Rhe Radix et Rhizoma, Natrim Sulfas, Pharbitidis Semen | Treating abdominal distension pain and constipation                                            |                                                |
| Niu Huang Qian Jin Powder    | Coptidis Rhizoma, Scorpio, Bombby Batryticus, Bovis Calculus, Cinnabaris, Borneolium Syntheticum, Arisaema Cum Bile, Gastrodiae Rhizoma, Glycyrrhizae Radix et Rhizoma | Clearing heat and detoxifying, calming nerves, curing children convulsion with high fever, hand and foot convulsions |                                                |
| Qin Lian Tablets             | Coptidis Rhizoma, Phellodendri Chinesis Cortex, Forsythiae Fructus, Scutellariae Radix, Paeoniae Radix Rubra, Glycyrrhizae Radix et Rhizoma | Treating headache and red eye, mouth and nose sores, hot dysentery, abdominal pain              |                                                |
| Shen Shuai Ning Capsules     | Coptidis Rhizoma, Radix Pseudostellariae, Praeparatum Pinelliae Rhizoma, Citri Reticulatae Pericarpium, Poria, Rhe Radix et Rhizoma, Glycyrrhizae Radix et Rhizoma, Salviae Miltiorrhizae Radix et Rhizoma, Achyranthisis Radix, Carthami Flos | Curing nausea, vomiting, poor appetite, bad urine, stool viscous                                |                                                |
| Wan Shi Niu Huang Qing Xin Pills | Coptidis Rhizoma, Bovis Calculus, Cinnabaris, Scutellariae Radix, Gardeniae Fructus, Curcumae Radix | Curing high fever irritability, insanity and children febrile convulsion                        |                                                |
| Wu Mei Pills                 | Coptidis Rhizoma, Mume Fructus, Asari Radix et Rhizoma, Zingiberis Rhizoma, Aconiti Lateralis Radix Praeparata, Zanthoxyli Pericarpium, Cinnamomi Ramulus, Ginseng Radix et Rhizoma, Phellodendri Chinesis Cortex, Angelicae Sinensis Radix | Curing abdominal pain, headache, mania, vomiting, and limbs cold.                               |                                                |
| Xiao Ke Ping Tablets         | Coptidis Rhizoma, Ginseng Radix et Rhizoma, Trichosanthis Radix, Asparagus Radix, Astragali Radix, Salviae Miltiorrhizae Radix et Rhizoma, Lycii Fructus, Astragali Complanati Semen, Puerariae Lobatae Radix, Anemarrhenae Rhizoma, Galla Chinesis, Schisandrae Chinesis Fructus | Curing diabetes                                                                               |                                                |
| Xiang Lian Pills             | Coptidis Rhizoma, Aucklandiae Radix                                                | Curing entritis, and bacillary dysentery, relieving pain                                        |                                                |
| Xiong Ju Shang Qing Pills    | Coptidis Rhizoma, Chuanxiong Rhizoma, Scutellariae Radix, Vitisii Fructus, Mentheae Haplocalyx Herba, Schizonepetae Spica, Ligustici Rhizoma et Radix, Saposhnikoviae Radix, Angelicae Dahuricae Radix, Chrysantheni Flos, Gardeniae Fructus, Forsythiae Fructus, Platycodonis Radix, Glycyrrhizae Radix et Rhizoma, Notopterygii Rhizoma et Radix | Treating migraine headache, nasal flow toothache, sore throat                                  |                                                |
Table 2. Continued.

| Preparation             | Main compositions                                                                 | Traditional and clinical uses                                                                 | References         |
|-------------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|--------------------|
| Yi Qing Granules        | Coptidis Rhizoma, Rhei Radix et Rhizoma, Scutellariae Radix                      | Treating pharyngitis, tonsil inflammation and gum inflammation                                 |                    |
| Zhu Che Pills           | Coptidis Rhizoma, Zingiberis Rhizoma Praeparatum, Angelicae Sinensis Radix, Moschus | Nourishing Yin and stopping dysentery, curing abdominal pain, diarrhea                          |                    |
| Zuo Jin Pills           | Coptidis Rhizoma, Euodiae Fructus                                               | Purging fire, soothing the liver, reconciling the intestines and stomach, analgesiastomach ache, mouth bitter noise, and vomiting |                    |
| Niu Huang Qing Re Powder| Coptidis Rhizoma, Scutellariae Radix, Gardeniae Fructus, Curcumae Radix, Bovis Calculus, Bubali Corun, Cinnabaris, Borneolum Syntheticum | Treating high fever spasm, limbs twitch, irritability restless, and phlegm turbid congestion   | (Zhong 1991)       |
| Niu Huang Xing Nao Pills| Coptidis Rhizoma, Bovis Calculus, Bubali Corun, Borneolum Syntheticicum, Scutellariae Radix, Gardeniae Fructos, Moschus, Cinnabaris, Margarita, Curcumae Radix | Curing high fever, coma convolution, irritable restlessness, infantile convulsions and insomnia   | (Zhong 1998)       |
| Qing Wei Huang Lian Pills| Coptidis Rhizoma, Glycyrrhiza Radix et Rhizoma, Platycodonis Radix, Gypsum Fibrosum, Anemarrhenae Rhizoma, Moutan Cortex, Trichosanthis Radix, Forsythiae Fructus, Scutellariae Radix, Gardeniae Fructus, Phellodendri Chinensis Cortex | Curing tongue sores, and sore throat                                                           | (Zhong 1998)       |
| San Huang Pills         | Coptidis Rhizoma, Rhei Radix et Rhizoma, Huang Cao                               | Curing dysentery, vomiting, hemoptysis and constipation                                         |                    |
| Xiao Er Qing Re Zhen Jing Powder| Coptidis Rhizoma, Arisaema Cum Bile, Scorpio, Bombyx Batryclicatus, Glycyrrhizae Radix et Rhizoma, Bovis Calculus, Cinnabaris, Borneolum Syntheticum, Bambusae Concretio Silicea | Curing hot convolution, hand-foot convulsions, cough, irritability and thirst                   | (Zhong 1991)       |
| San Huang Qing Jie Pills| Coptidis Rhizoma, Scutellariae Radix, Forsythiae Fructus, Phellodendri Chinensis Cortex, Lonicerae Japonicae Flos | Curing fever, cough, sore throat, hot leaching and diarrhea                                      | (Guo 2002)         |
| Xie Li Xiao Pills       | Coptidis Rhizoma, Atractylodis Rhizoma, Alba Paoniae Radix, Aucklandiae Radix, Euodiae Fructus, Magnoliae Officinalis Cortex, Arealce Semen, Auranti Fructus, Citri Reticulatae Pericarpium, Alismatis Rhizoma, Poria, Glycyrrhizae Radix et Rhizoma | Treating acute enteritis, colitis, and dysentery                                               |                    |
| Huang Lian Jie Du Pills | Coptidis Rhizoma, Phellodendri Chinensis Cortex, Scutellariae Radix, Rhei Radix et Rhizoma, Talcum, Clermatidis Armandii Caulis, Gardeniae Fructus | Treating sore mouth, headache, constipation, red eyes, heart-burn, sore throat                  |                    |
| Geng Nian Xin Capsules  | Coptidis Rhizoma, Cinnamomi Cortex, Alpiniae Oxyphyllae Fructus, Lycii Fructus, Corni Fructus, Ligustri Lucidi Fructus, Cuscutae Semen, Acori Tatarinowii Rhizoma, Rehmanniae Radix, Polygalae Radix, Ziziphi Spinosa Semen, Citri Reticulatae Pericarpium, Alliums Rhizoma | Curing heart palpitations, insomnia, dizziness, tinnitus, and backache                          | (Chinese Pharmacopoeia Commission 2008) |

Figure 1. The whole plants and rhizomes of C. chinensis (A), C. chinensis (B) and C. teeta (C).
Table 3. Partial list of chemical compounds isolated from CR.

| Classification | Number | Ingredient name | Reference |
|----------------|--------|-----------------|-----------|
| Alkaloids       | 1      | Berberine       | (Noguchi et al. 1978) |
|                 | 2      | Berberrubine    | (Li ZF et al. 2012) |
|                 | 3      | Coptisine       | (Wang et al. 2014) |
|                 | 4      | Palmatine       |           |
|                 | 5      | Epiberberine    | (Mizuno et al. 1992) |
|                 | 6      | Columbamine     | (Ikuta and Itohawa 1989) |
|                 | 7      | Tetradehydrocouverine | (Chen et al. 2008) |
|                 | 8      | Jatrorrhizine   | (Li ZF et al. 2012) |
|                 | 9      | Groenlandicine  |           |
|                 | 10     | Berberastine    | (Li ZF et al. 2012) |
|                 | 11     | Worenine        |           |
|                 | 12     | 8-Oxyberberine  | (Wang et al. 2014) |
|                 | 13     | 8-Oxycoptisine  |           |
|                 | 14     | (-)-5-Hydroxy-8-oxyberberine | (Wang et al. 2014) |
|                 | 15     | 8-Oxyepiberberine | (Yang et al. 2014) |
|                 | 16     | 8-Oxyberberrubine |           |
|                 | 17     | 8-Oxycoptisine  |           |
|                 | 18     | (-)-5-Hydroxy-8-oxyberberine | (Wang et al. 2014) |
|                 | 19     | Tetrahydroberberine | (Yang et al. 2014) |
|                 | 20     | 8,13-Dioxocoptisine hydroxide | (Ma et al. 2013) |
|                 | 21     | 1,3-Dioxygenol(4,5-g)-isoquinolin-5(6H)-one | (Wang et al. 2007) |
|                 | 22     | Noroxhydastinine |           |
|                 | 23     | Corydalmine     |           |
|                 | 24     | Thalifoline      |           |
|                 | 25     | 6-[[1,3][Dioxygenol(4,5-g)-isoquinolin-5-carboxyl]-2,3-dimethoxy benzoic acid methyl ester | (Wang et al. 2014) |
|                 | 26     | Berbithine       |           |
|                 | 27     | Coptissonine     | (Yang et al. 2014) |
|                 | 28     | Tetrandrine      |           |
|                 | 29     | Obamegine        |           |
|                 | 30     | Magnoflorine     |           |
|                 | 31     | Sanguinarine     | (Tomita and Kura 1956) |
|                 | 32     | Norsanguinarine  | (Mizuno et al. 1988) |
|                 | 33     | Oxysanguinarine  |           |
|                 | 34     | 6-Acetonyl-5,6-dihydrosanguinarine |           |
|                 | 35     | Chileneine       | (Yang et al. 2014) |
|                 | 36     | Z-N-Ferulytyramine | (Li ZF et al. 2012) |
|                 | 37     | E-N-Ferulytyramine | (Ma H et al. 2013) |
|                 | 38     | 3-Hydroxy-1-(4-hydroxyphenethyl) pyrrolidine-2,5-dione | (Li ZF et al. 2012) |
|                 | 39     | 4'-[Formyl-5-(hydroxymethyl)-1H-pyrrol-1-yl] butanoate | (Ma H et al. 2013) |
|                 | 40     | 8,9-Dihydroxy-1,5,6,10-b-tetrahydro-2-isopyrrolo(2,1-az)-isoquinolin-5-one | (Li, et al. 2012) |
|                 | 41     | E-N-pyrrolidinone-5(S)-carboxylate |           |
|                 | 42     | Methyl-5-hydroxy-2-pyridinecarboxylate |           |
|                 | 43     | 1H-indole-3-carboxaldehyde |           |
|                 | 44     | Choline          | (Chen L et al. 2012) |
|                 | 45     | Woorenogenin     | (Chen et al. 2016) |
|                 | 46     | Woorenoside I    | (Yoshikawa et al. 1995) |
|                 | 47     | Longifoloside A  | (Meng et al. 2013) |
|                 | 48     | Woorenoside II   | (Yoshikawa et al. 1995) |
|                 | 49     | Woorenoside V    |           |
|                 | 50     | Woorenoside III  |           |
|                 | 51     | Woorenoside IV   |           |
|                 | 52     | (+)-Pinoresinol  |           |
|                 | 53     | (+)-Medioresinol |           |
|                 | 54     | (+)-Pinoresinol glucoside |           |
|                 | 55     | (+)-Pinoresinol-4,4'-O-[beta]-o-diglucopyranoside | (Yoshikawa et al.1997) |
|                 | 56     | (+)-Syringaresinol glucoside | (Meng et al. 2013) |
|                 | 57     | (+)-Lariciresinol | (Hirano et al. 1997) |
|                 | 58     | (±)-5,5'-Dimethoxylariciresinol | (Li XG et al. 2012) |
|                 | 59     | (+)-5'-Methoxylariciresinol | (Chen L et al. 2012) |
|                 | 60     | (+)-Lariciresinol glucoside | (Chen et al. 2016) |
|                 | 61     | 75, 8R(+)—Lariciresinol-4,4'-O-[beta]-o-diglucopyranoside | (Yoshikawa et al.1997) |
|                 | 62     | Lanicpseide A    | (Chen et al. 2016) |
|                 | 63     | 9-Acetyl lanicpseide B |           |
|                 | 64     | (+)-Isolariciresinol |           |
|                 | 65     | Isolariciresinol-9-O-[beta]-o-glucopyranoside | (Li XG et al. 2012) |
|                 | 66     | Woorenoside XI   | (Yoshikawa et al.1997) |
|                 | 67     | Cleomiscosin A   | (Mizuno et al. 1992) |
|                 | 68     | Aquillochon      | (Min et al. 1987) |
|                 | 69     | 2,3-bis[4-(4-Hydroxy-3,5-dimethoxyphenyl)-methyl]-1,4-butanediol | (Li XG et al. 2012) |
|                 | 70     | secisolariciresinol | (Chen L et al. 2012) |
|                 | 71     | Erythro-gaiacylglycerol-8-04'-[coniferlyalcohol] ether | (Yoshikawa et al.1997) |
|                 | 72     | Threo-gaiacylglycerol-8-04'-[coniferly alcohol] ether |           |
|                 | 73     | Woorenoside V    | (Yoshikawa et al.1997) |

(continued)
Alkaloids are the main active ingredients of coptidis, and isoquinoline alkaloids account for a large proportion, with berberine (I) as the most representative compound. Berberine is one of the most abundant ingredients (Cooper et al. 1970) at 4.5–8%, although this varies in different varieties of CR. In addition to berberine, CR contains over 30 different kinds of isoquinoline alkaloids, which can be divided into the following subtypes according to their structures: protoberberines, simple isoquinolines, aporphines and benzylisoquinolines (Figures 2–5).

### Table 3. Continued.

| Classification | Number | Ingredient name | Reference |
|----------------|--------|-----------------|-----------|
| Simple phenylpropanoids | 74 | Dihydrodehydrodiconiferyl alcohol | (Li XG et al. 2012) |
| | 75 | Wooreno | (Yoshikawa et al. 1997) |
| | 76 | 2-Octadeyl cafeeate | (Yang et al. 2018) |
| | 77 | E-3-Methoxyxycinnamic acid | (Li XG et al. 2012) |
| | 78 | Ferulic acid | (Yang et al. 2018) |
| | 79 | Ethyl ferulate | (Yang et al. 2018) |
| | 80 | N-Butyl ferulate | (Ma H et al. 2013) |
| | 81 | p-Hydroxyphenethyl E-ferulate | (Yang et al. 2018) |
| | 82 | E,3,4-Dimethoxycinnamic acid | (Yang et al. 2018) |
| | 83 | 4-O-Feruloylquinic acid | (Yang et al. 2018) |
| | 84 | Methyl 4-O-feruloylquinic acid | (Yang et al. 2018) |
| | 85 | Ethyl 4-O-feruloylquinic acid | (Yang et al. 2018) |
| | 86 | 4-O-Feruloylquinic acid butyl ester | (Yang et al. 2018) |
| | 87 | 5-O-Feruloylquinic acid | (Yang et al. 2018) |
| | 88 | Methyl 5-O-feruloylquinic acid | (Yang et al. 2018) |
| | 89 | Ethyl 5-O-feruloylquinic acid | (Yang et al. 2018) |
| | 90 | 5-O-(Phenyl)quinic acid butyl ester | (Yang et al. 2018) |
| | 91 | Chlorogenic acid | (Chen L et al. 2012) |
| | 92 | Methyl 3-O-feruloylquinic acid | (Yang et al. 2018) |
| | 93 | N-Butyl 3-O-feruloylquinic acid | (Yang et al. 2018) |
| | 94 | 3-(4′-Hydroxyphenyl)-(2R)-lactic acid | (Yang et al. 2018) |
| | 95 | 3-(3′,4″-Hydroxyphenyl)-(2R)-lactic acid | (Yang et al. 2018) |
| | 96 | 3-(3′,4″-Dihydroxyphenyl)-(2R)-lactic acid-4′-O-β-D-glucopyranoside | (Yang et al. 2018) |
| | 97 | Methyl-3-(4′-O-β-D-glucopyranosyl-3′,4″-di-β-D-glucopyranosyl)-lactate | (Yang et al. 2018) |
| | 98 | Methyl-3,4-dihydroxyphenyl lactate | (Yang et al. 2018) |
| | 99 | Ethyl-3,4-dihydroxyphenyl lactate | (Yang et al. 2018) |
| | 100 | N-Butyl-3,4-dihydroxyphenyl lactate | (Yang et al. 2018) |
| | 101 | 3-(2,3,4-Trihydroxyphenyl) propanoic acid | (Yang et al. 2018) |
| | 102 | 6,8-Dimethyl-3,5,7-trihydroxyfavone | (Yang et al. 2018) |
| | 103 | Rhamnetin | (Chen L et al. 2012) |
| | 104 | Wogonin | (Chen L et al. 2012) |
| | 105 | 7,4′-Dihydroxy-5-methoxyfavanone | (Chen L et al. 2012) |
| | 106 | 2′,4′-Dihydroxy-6′-methoxydihydrochalcone | (Chen L et al. 2012) |
| | 107 | Coptiside I | (Fujisawa et al. 1976) |
| | 108 | Coptiside II | (Fujisawa et al. 1976) |
| | 109 | Woorenoside XII | (Fujisawa et al. 1976) |
| | 110 | Limonin | (Yang et al. 2018) |
| | 111 | 3,4-Dihydroxyphenylethyl alcohol | (Yang et al. 2018) |
| | 112 | 3′,4″-Hydroxyphenethyl alcohol 1-O-β-D-glucopyranoside | (Yang et al. 2018) |
| | 113 | 3,5-Dihydroxyphenethyl alcohol 3-O-β-D-glucopyranoside | (Yang et al. 2018) |
| | 114 | Protocatechuic aldehyde | (Yang et al. 2018) |
| | 115 | Gentisic acid-5-O-β-D-glucopyranoside | (Yang et al. 2018) |
| | 116 | Apocynol | (Yang et al. 2018) |
| | 117 | 1,2-Dihydroxy-benzene | (Yang et al. 2018) |
| | 118 | Protocatechuic acid | (Yang et al. 2018) |
| | 119 | Vanillic acid | (Yang et al. 2018) |
| | 120 | Vanillic acid-4-O-β-D-glucopyranoside | (Yang et al. 2018) |
| | 121 | Protocatechuic acid methyl ester | (Yang et al. 2018) |
| | 122 | Protocatechuic acid ethyl ester | (Yang et al. 2018) |
| | 123 | Woorenoside VI | (Yang et al. 2018) |
| | 124 | Woorenoside VII | (Yang et al. 2018) |
| | 125 | Woorenoside VIII | (Yang et al. 2018) |
| | 126 | Woorenoside IX | (Yang et al. 2018) |
| | 127 | cyclo-(Phe-Val) | (Yang et al. 2018) |
| | 128 | cyclo-(Phe-Leu) | (Yang et al. 2018) |
| | 129 | β-Sitosterol | (Yang et al. 2018) |

### Alkaloids

Alkaloids are the main active ingredients of coptidis, and isoquinoline alkaloids account for a large proportion, with berberine (I) as the most representative compound. Berberine is one of the most abundant ingredients (Cooper et al. 1970) at 4.5–8%, although this varies in different varieties of CR. In addition to berberine, CR contains over 30 different kinds of isoquinoline alkaloids, which can be divided into the following subtypes according to their structures: protoberberines, simple isoquinolines, aporphines and benzylisoquinolines (Figures 2–5).

### Protoberberines

The protoberberine alkaloids are derived from benzylisoquinolines through phenolic oxidation and coupling with the isoquinoline N-methyl group, which becomes the 'berberine bridge' carbon. Tetracyclic rings, which are based on the dibenzo quinolizidine system, form the main matrices of protoberberine (Cooper et al. 1970). According to the position of the double bond and whether the nitrogen atom has a positive charge, the protoberberines can be divided into 10 subtypes, as shown in Figure 2. The following is a list of 20 representative protoberberine compounds that can be found in CR. Among these subtypes, type 3 is the most...
common one in CR: Berberine (1), berberrubine (2), coptisine (3), palmatine (4), epiberberine (5), columbamine (6), tetrahydroscoulerine (7), jatrorrhizine (8), groenlandicine (9), berberastine (10), worenine (11), 8-oxyberberine (12), 8-oxycoptisine (13), 3-hydroxy-2-methoxy-9,10-methylenedioxy-8-oxyprotoberberine (14), 8-oxyepiberberine (15), 8-oxyberberrubine (16), (-)-5-hydroxy-8-oxyberberine (17), (+)-5-hydroxy-8-oxyberberine (18), tetrahydroscoulerine (19), and 8,13-dioxocoptisine hydroxide (20) (Yoshikawa et al. 1995; Wang et al. 2007; Li ZF et al. 2012; Fan et al. 2014).}

**Simple isoquinolines**

Alkaloids belonging to this subtype are fused together by a benzene ring and a pyridine; the nitrogen atom is in position 2 (which differs from quinoline) (Figure 3). Simple isoquinolines usually have a smaller in molecular weight and have no complex branched chains. The simple isoquinolines in CR include 1,3-dioxolo[4,5-g]isoquinolin-5(6H)-one (21), noroxyhydrastinine (22), corydalidine (23), and thalifoline (24) (Wang et al. 2007; Li ZF et al. 2012; Fan et al. 2014).

**Benzylisoquinolines**

Benzylisoquinolines are divided into 1-benzylisoquinolines and bis-benzylisoquinolines. 1-Benzylisoquinolines are compounds with isoquinoline matrices and a benzyl group at position 1. Furthermore, bis-benzylisoquinolines are formed by a combination of two 1-benzylisoquinolines via 1-3 ether bonds, such as 6-([1,3]dioxolo[4,5-g]isoquinoline-5-carbonyl)-2,3-dimethoxy benzoic acid methyl ester (25), berbithine (26), coptisonine (27), tetrandrine (28), and obamegine (29) (Wang et al. 2007).

**Other alkaloids**

CR also contains other subtypes of alkaloids, such as magnoflorine (30) (Tomita and Kura 1956), which is an active ingredient belonging to the aporphine alkaloids. Moreover, some benzopeneanthridine alkaloids can also be found in certain specific CR varieties. For example, sanguinarine (31), norsanguinarine (32),
oxysanguinarine (33), and 6-acetonyl-5,6-dihydrosanguinarine (34) can be found in *C. japonica* (Maiti et al. 1982). CR also includes some small alkaloids, which are not representative compounds, such as chilenine (35) (Fan et al. 2014), \(z\)-N-ferulyl-tyramine (36), \(E\)-N-ferulyltyramine (37), 3-hydroxy-1-(4-hydroxyphenethyl) pyrrolidine-2,5-dione (38), and 4'-[formyl-5-(hydroxymethyl)-1-yrrol-1-yl] butanoate (39) (Wang et al. 2007); and 8,9-dihydroxy-1,5,6,10-\(b\)-tetrahydro-2\(n\)-pyrrolo[2,1-\(a\)]-isoquinolin-5-one (40), ethyl-2-pyrrolidinone-5(S)-carboxylate (41) (Li et al. 2012), methyl-5-hydroxy-2-pyridinecarboxylate (42), 1\(H\)-indole-3-carboxaldehyde (43), and choline (44) (Chen et al. 2012; Li XG et al. 2012; Li ZF et al. 2012; Ma H et al. 2013).

Figure 4. Alkaloids numbered 1–27 in *Coptidis Rhizoma.*
Phenylpropanoids are a class of compounds that are linked together by a benzene ring and three-carbon chains. They are a large class of organic compounds that exist widely exist in natural medicines and can be subdivided into many different subclasses. The molecular weight of phenylpropanoids in CR varies greatly, as do their structures. Both phenylpropanoids and their glycosides were reported in CR.

**Phenylpropanoids**

![Chemical structures of various phenylpropanoids](image-url)

Figure 5. Alkaloids numbered 28–44 in Coptidis Rhizoma.
Lignans

Lignans are important natural constituents with various pharmacological activities. Special kinds of phenylpropanoids, which are a combination of two or more simple phenylpropanoids, were comprehensively investigated and isolated from CR (Min et al. 1987; Hirano et al. 1997; Yoshikawa 1997a; Chen L et al. 2012; Li XG et al. 2012; Wang et al. 2012). These constituents include woorenogenin (45), woorenoside I (46), longifolroside A (47), woorenoside II (48), woorenoside V (49), woorenoside III (50), woorenoside IV (51), (+)-piroresinol (52), (+)-magnoliresinol (53), (+)-piroresinol glucoside (54), (+)-piroresinol-4,4′-O-β-D-diglucopyranoside (55), (+)-syringaresinol glucoside (56), (+)-lariciresinol (57), (+)-5,5′-dimethoxylariciresinol (58), (+)-5′-methoxylariciresinol (59), (+)-lariciresinol glucoside (60), 7S, 8R, 8′R(-)-lariciresinol-4,4′-O-β-D-diglucopyranoside (61), lanicepside A (62), 9-acetyl lanicepside B (63), (+)-isolariciresinol (64), isolarisiresinol-9-O-β-D-glucopyranoside (65), woorenoside XI (66), cleomiscosin A (67), aquillochin (68), 2,3-bis-[[(4-hydroxy-3,5-dimethoxyphenyl)-methyl]-1,4-butanediol (69), secoisolariciresinol (70), erythro-gaiaclglycerol-8-O-4′-
(coniferyl alcohol) ether (71), threo-guaiacylglycerol-8-O-4′-(coniferyl alcohol) ether (72), woorenoside X (73), dihydrodehydrodi-coniferyl alcohol (74), and wooreno (75) (Figures 6–7).

**Simple phenylpropanoids**

Ferulic acid and its derivatives are the most common simple phenylpropanoids in herbal medicine. In addition to ferulic acid, we can also find other simple phenylpropanoids. These derivatives usually form esters with carboxyl groups (Yahara et al. 1985; Yoshikawa et al. 1995, 1997a; Hirano et al. 1997; Chen L et al. 2012; Li et al. 2012; Meng et al. 2013; Fan et al. 2014). These compounds include Z-octadecyl cafeate (76), E-3-methoxycinnamic acid (77), ferulic acid (78), ethyl ferulate (79), N-butyl ferulate (80), p-hydroxyphenethyl E-ferulate (81), E-3,4-dimethoxyxycinnamic acid (82), 4-O-feruloylquinic acid (83), methyl 4-O-feruloylquicinate (84), ethyl-4-O-feruloylquicinate (85),...
4-O-feruloylquinic acid butyl ester (86), 5-O-feruloylquinic acid (87), methyl-5-O-feruloylquinic acid (88), ethyl-5-O-feruloylquinic acid (89), 5-O-feruloylquinic acid butyl ester (90), chlorogenic acid (91), methyl-3-O-feruloylquinic acid (92), N-butyl-3-O-feruloylquinic acid (93), 3-(4′-hydroxyphenyl)-(2R)-lactic acid (94), 3-(3′,4′-dihydroxyphenyl)-(2R)-lactic acid (95), 3-(3′,4′-dihydroxyphenyl)-(2R)-lactic acid-4′-O-β-D-glucopyranoside (96), methyl-3-(4′-O-β-D-glucopyranosyl-3′,4′-dihydroxyphenyl) lactate (97), methyl-3,4-dihydroxyphenyl lactate (98), ethyl-3,4-dihydroxyphenyl lactate (99), N-butyl-3,4-dihydroxyphenyl lactate (100), and 3-(2,3,4-trihydroxyphenyl) propanoic acid (101) (Figure 8).

Flavonoids

Previous research reported that CR also contains certain flavonoids, mainly including 6,8-dimethyl-3,5,7-trihydroxyflavone (102), rhamnetin (103), wogonin (104) (Meng et al. 2013), 7,4′-dihydroxy-5-methoxyxavone (105), 2′,4′,6′-trihydroxy-5′-methoxydihydrochalcone (106) (Min et al. 1987), coptiside I (107), coptiside II (108) and woorenoside XII (109) (Fujiwara et al. 1976; Yoshikawa et al. 1997b) (Figure 9).

Other compounds

Other compounds isolated from CR include limonin (110), 3,4-dihydroxyphenylethyl alcohol (111), 3′,4′-dihydroxyphenethyl alcohol 1-O-β-D-glucopyranoside (112), 3,5-dihydroxyphenethyl alcohol-3-O-β-D-glucopyranoside (113), protocatechuic aldehyde (114), gentisic acid-5-O-β-D-glucopyranoside (115), apocynol (116), 1,2-dihydroxy-benzene (117), protoatechuic acid (118), vanillic acid (119), vanillic acid-4-O-β-D-glucopyranoside (120), protocatechuic acid methyl ester (121), protocatechuic acid ethyl ester (122), woorenoside VI (123), woorenoside VII (124), woorenoside VIII (125), woorenoside IX (126), cyclo-(Phe-Val) (127), cyclo-(Phe-Leu) (128), and β-sitosterol (129) (Yahara et al. 1985; Yoshikawa et al. 1997; Wang et al. 2007; Li XG et al. 2012; Li ZF et al. 2012; Ma H et al. 2013; Meng et al. 2013; Yang et al. 2014) (Figure 10).
Pharmacology

Anti-pathogenic microorganism activity

Increasing research has been devoted to investigating the anti-pathogenic microorganism effects of CR, and its antibacterial, antiviral, and antifungal effects have been comprehensively studied and validated. Importantly, berberine has been recognized as the most important active monomer in this plant (Table 4).

Antibacterial effect

Berberine can inhibit Gram-positive (G⁺) bacteria such as *Streptococcus agalactiae, Staphylococcus aureus, S. mutans, Bacillus anthracis, S. suis, and Enterococcus faecium* (Choi et al. 2007; Fan et al. 2008; Wang et al. 2014; Peng et al. 2015); and Gram-negative (G⁻) bacteria such as *Actinobacillus pleuropneumoniae* (Kang et al. 2015), *Shigella dysenteriae* (Kong et al. 2010), and *Escherichia coli* (Boberek et al. 2010). Interestingly, alkaloids isolated from CR, especially epiberberine, can act as urease inhibitors to treat *Helicobacter pylori* infection (Tan et al. 2017). In 2014, Chen et al. reported that CR extracts (CRE) significantly inhibited *Salmonella typhimurium* with a minimum bactericidal concentration (MBC) of 12.5 mg/mL. Another study reported that although CRE had no effect on bacteria such as *Pseudomonas aeruginosa, Proteus mirabilis, and Proteus vulgaris*, after processing with ginger, it showed a marked inhibitory effect against these bacteria, especially *P. aeruginosa* (Li 2015).
Previous studies revealed that the antibacterial effects of CR and its active constituents were attributed to damaging the cell membrane, inhibiting protein and DNA synthesis, blocking bacterial division and development, and disturbing the formation of the Z-rings to inhibit the cell division protein FtsZ (Chu et al. 2014; Xue D et al. 2015; Ming et al. 2016). The antibacterial effect of CR alkaloids against G⁺ bacteria was stronger than that against G⁻ bacteria, which could be explained by different the cell membrane structures of the pathogens (Yong et al. 2007). Kong W et al. (2009) performed a comprehensive analysis including the growth rate constant $k$, maximum power output of the log phase $P_{m,\text{log}}$, total heat output of the log phase $Q_{t,\text{log}}$, generation time $t_{g}$, growth inhibitory ratio $I$, and half-inhibitory concentration of the drugs (IC₅₀), and revealed that the antibacterial activities against *E. coli* of the four alkaloids from CR were in the order of berberine > coptisine > palmatine > jatrorrhizine.

**Antiviral effect**

Previous investigations revealed that CR and berberine have inhibitory effects against respiratory syncytial virus, influenza virus, enterovirus 71, herpes simplex virus, coronavirus and cytomegalovirus. In addition, studies showed that the inhibitory effects of berberine were mediated by downregulating cellular

Figure 10. Other compounds in Coptidis Rhizoma.
| Pathogenic microorganism                  | Extract/compound (number) | In vitro/In vivo | Mechanism                                                                 | Minimal active concentration/dose | Reference               |
|-----------------------------------------|---------------------------|------------------|---------------------------------------------------------------------------|----------------------------------|-------------------------|
| *Streptococcus agalactiae*              | 1                         | *in vitro*       | Damaging the structure of bacterial cell membrane and inhibiting synthesis of protein and DNA | \( \text{MIC} = 231.9 \, \mu \text{M} \) (Peng et al. 2015) |
| *Actinobacillus pleuropneumoniae*       | 1                         | *in vitro*       | Restrainting DNA and protein syntheses, inhibiting the cleavage of bacteria, blocking the division and development of bacteria | \( \text{MIC} = 929.1 \, \mu \text{M} \) (Kang et al. 2015) |
| *Staphylococcus aureus*                 | CRE                       | *in vitro*       | Not mentioned                                                              | \( \text{MIC} = 77.8 \, \mu \text{g/mL} \) (Fan et al. 2008) |
| Coagulase-negative Staphylococcus strains| 1                         | *in vitro*       | Not mentioned                                                              | \( \text{MIC} = 47.6 \, 152.2 \, \mu \text{M} \) (Wojtyczka et al. 2014) |
| *Shigella dysenteriae*                  | 1                         | *in vitro*       | Not mentioned                                                              | \( \text{MIC} = 74.3 \, \mu \text{M} \) (Kong et al. 2010) |
| *Escherichia coli*                      | 1                         | *in vitro*       | Heavily perturbing the formation of the Z-rings, inhibiting the cell division protein FtsZ | \( \text{MIC} = 1.5-4.5 \, \mu \text{M} \) (Boberek et al. 2010) |
| *Salmonella typhimurium*                | 1                         | *in vivo*        | As a LPS antagonist and blocking the LPS/TLR4 signaling                    | \( \text{MIC} = 0.20 \, \text{g/kg} \) (mice), \( 0.05 \, \text{g/kg} \) (rabbit) (Chu et al. 2014) |
| *Helicobacter pylori*                   | 5                         | *in vitro*       | Binding to the active-site sulfydryl groups                                | \( \text{IC}_{50} = 3.0 \, \mu \text{M} \) for HPU and \( 2.3 \, \mu \text{M} \) for JBU (Tan et al. 2017) |
| *Helicobacter pylori*                   | 1                         | *in vitro*       | Not mentioned                                                              | \( \text{MIC} = 74.3-743.2 \, \mu \text{M} \) (Song et al. 2014) |
| *Salmonella Typhimurium*                | CRE                       | *in vitro*       | Regulation of the immune response                                          | \( \text{MBC} = 12.5 \, \text{mg/mL} \) for *S. Typhimurium* \( \text{MBC} = 25 \, \text{mg/mL} \) for *ST21* (Chang et al. 2014) |
| *Aeromonas hydrophila*                  | Total alkaloids            | *in vitro*       | Injuring membrane by increasing membrane lipid fluidity and changing conformation of membrane proteins, and reducing the secretion of virulence factors | \( \text{MIC} = 62.5 \, \text{mg/L} \) (Xue et al. 2015) |
| *Staphylococcus aureus*                 | 1                         | *in vitro*       | Not mentioned                                                              | \( \text{IC}_{50} = 169.5 \, \mu \text{M} \) (Fan et al. 2008) |
|                                          | 3                         | *in vitro*       | Downregulation of JNK and NF-kappa B Activation                            | \( \text{EC}_{50} = 6.77 \, \mu \text{M} \) for HSV-1 (Song et al. 2014) |
|                                          | 4                         | *in vitro*       | Inhibiting the virus infection, repressing inflammatory substances release | \( \text{IC}_{50} = 74.3 \, \text{mg/kg} \) (HSV-2) (Wu et al. 2011) |
|                                          | 5                         | *in vitro*       | Predominantly targeting the ERK arm of MAPK signalling                     | \( \text{EC}_{50} = 2.0 \, \text{mg/mL} \) (Kim et al. 2008) |
|                                          | 8                         | *in vitro*       | Downregulating autophagy and MEK/ERK signaling pathway                     | \( \text{IC}_{50} = 7.43-10.25 \, \mu \text{M} \) (Wang et al. 2017) |
| *Enterovirus 71*                        | CRE                       | *in vitro*       | Downregulating autophagy and MEK/ERK signaling pathway                     | \( \text{IC}_{50} = 7.43-10.25 \, \mu \text{M} \) (Wang et al. 2017) |
| *H1N1 neuraminidase (NA-1)*             | CRE                       | *in vitro*       | Inhibiting H1N1 neuraminidase (NA-1)                                       | \( \text{IC}_{50} = 96.1 \, \mu \text{g/mL} \) (Zhou et al. 2017) |
|                                          | 4                         | *in vitro*       | Inhibiting H1N1 neuraminidase (NA-1)                                       | \( \text{IC}_{50} = 90.5 \, \mu \text{M} \) (Kim et al. 2008) |
|                                          | 8                         | *in vitro*       | Inhibiting RNA-dependent RNA polymerase or proteases, affecting virus assembly or release | \( \text{IC}_{50} = 0.68 \, \mu \text{M} \) (Hayashi et al. 2007) |
| *Coronavirus*                           | CRE                       | *in vitro*       | Inhibition of RNA-dependent RNA polymerase or proteases, affecting virus assembly or release | \( \text{EC}_{50} = 2.0 \, \text{mg/mL} \) (Kim et al. 2008) |
| *Candida albicans*                      | berberine chloride        | *in vitro*       | Inhibition of RNA-dependent RNA polymerase or proteases, affecting virus assembly or release | \( \text{IC}_{50} = 7.43-10.25 \, \mu \text{M} \) (Wang et al. 2017) |
| *Human cytomegalovirus* (HCMV)          | berberine chloride        | *in vitro*       | Inhibition of RNA-dependent RNA polymerase or proteases, affecting virus assembly or release | \( \text{IC}_{50} = 7.43-10.25 \, \mu \text{M} \) (Wang et al. 2017) |
c-Jun N-terminal protein kinase (JNK) and NF-kappa B activation (Hayashi et al. 2007), suppressing mitogen-activated protein kinase (MAPK) or MAPK/ERK kinase 1 (MEK)/extracellular signal-regulated kinase (ERK) signalling (Shin et al. 2015; Varghese et al. 2016). Furthermore, berberine could suppress the EV71-induced autophagy by activating the AKT protein and inhibiting the phosphorylation of JNK and phosphatidylinositol-4,5-bisphosphate 3-kinase III (PI3KIII) (Wang HQ et al. 2017). H1N1 infection could be also suppressed by a water extract of CR, during which the main alkaloids served as neuraminidase inhibitors, and among them, palmatine was the most effective, with an IC50 of 50.5 μM (Zhou et al. 2017). The specific inhibition of West Nile virus (WNV) NS2B-NS3 protease and viral propagation by palmatine, with an IC50 of 96 mM, was investigated. Palmatine was also effective against dengue virus and yellow fever virus (Jia et al. 2010).

**Antifungal effect**

Berberine showed a weak inhibitory effect on *C. albicans* when used alone; while combined with fluconazole, the MIC value decreased sharply to 14.27 μM (Iwazaki et al. 2010). Other research showed that the antifungal effect of berberine was based on its ability to impair mitochondrial function, the generation of reactive oxygen species (ROS), targeting the cell wall integrity pathway, and affecting heat shock transcription factor 1 (HSF1) (Dhamgaye et al. 2014).

**Protective effects on the cardiovascular system**

Cardiovascular diseases (CVDs) involving the heart or blood vessels are the leading cause of death in worldwide. It is estimated that by 2030, over 23 million people will die from CVDs each year (Mendis et al. 2011). Importantly, CR can exert significant beneficial effects on major risk factors of CVDs, including antiatherosclerotic, antihyperlipidemic, antidiabetic, antihepatic steatotic effects. Recent studies have shown that alkaloids in CR can protect against CVDs, such as coronary heart diseases, myocardial ischemia-reperfusion injury, heart failure, arrhythmia, and hypertension (Feng 2008; Mei 2011; Yong et al. 2011) (Table 5).

**Anti-atherosclerotic effect**

Atherosclerosis (AS) commonly occurs in the subendothelial space (intima) of arteries and is triggered by endothelial dysfunction and subendothelial lipoprotein retention (Tabas et al. 2015). It has been reported that CR and its main alkaloids, such as berberine and coptisine, could effectively prevent the development of AS, and the potential mechanisms are correlated with suppressing ROS mediated oxidation (Xu RX et al. 2017), and halting chronic inflammatory reactions via inhibition of intracellular inflammation signaling pathways (Feng et al. 2016, 2017). In particular, berberine could inhibit atherogenesis by reducing oxidative stress and the expression of adhesion molecules in the aorta, and increasing the levels of uncoupling protein 2 (UCP2) (Wang et al. 2011). Another CR component, magnoflorine, could inhibit the copper-mediated (Cu2+) oxidation of various low-density lipoprotein (LDL) forms by increasing the lag time of conjugated diene formation and suppressing the generation of thiobarbituric acid reactive substances (TBARS) (Hung et al. 2007). The accumulation of foam cells in the subendothelial space is an indispensable step for the initiation and progression of AS. Berberine treatment could suppress foam cell formation, as well as the accumulation of lipid and cholesterol. The mechanism involves the activation of adenosine 5-monophosphate (AMP)-activated protein kinase (AMPK)-SIRT1-peroxisome proliferators-activated receptor γ2 (PPAR-γ) pathway and a decrease in ox-LDL uptake (Chi et al. 2014). Berberine can stabilize atherosclerotic plaques by inhibiting the expressions of matrix metalloproteinase 9 (MMP-9) and extracellular matrix metalloproteinase inducer (EMMPRIN) by suppressing activation of the p38 pathway (Huang et al. 2011).

**Anti-hyperlipidemic effect**

Hyperlipidemia, characterized by increased levels of blood lipids, has been implicated as a contributing factor to the development of cardiovascular diseases. The main mechanism of resisting hyperlipidemia is related to inhibiting lipogenesis and promoting the use, conversion and excretion of lipid (Iii et al. 2014). Alkaloids derived from CR, including berberine, coptisine, palmatine, epiberberine and jatrorrhizine, appeared to prevent body weight gain, reduce serum levels of total cholesterol (TC), triglyceride (TG) and low-density lipoprotein–cholesterol (LDL-c) and increase high-density lipoprotein–cholesterol (HDL-c) and promoted the excretion of total bile acids (TBA) in faeces (He et al. 2016; Yang W et al. 2016). The effect of berberine is mainly related to upregulating the LDL receptor (LDLR) and Cytochrome P450 7A1 (CYP7A1), while downregulating 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) (Ma et al. 2016). In addition, palmatine and epiberberine, which could also be beneficial to treat hyperlipidaemia and downregulate apical sodium dependent bile acid transporter (ASBT) (Zou et al. 2016; He et al. 2017). The sterol regulatory element-binding proteins (SREBPs) are transcription factors that regulate cholesterol by binding to the promoters of genes such as those encoding LDLR and HMG-CoA synthase. Interestingly, administration of coptisine, berberine and palmatine could activate SREBP2 (Kai et al. 2016). Besides these main alkaloids of CR, some minor alkaloids, such as berbamine, could also exert effects on hypercholesterolemic zebrafish by upregulating cholesterol transport and bile acid synthesis (Han et al. 2017).

**Anti-obesity**

Obesity is a pathological condition characterized by excessive body fat that often leads to cardiovascular diseases (Ashraf and Basweja 2013). 3T3-L1 cells are commonly used to detect fat metabolism. Previous studies revealed that five CR alkaloids (berberine, coptisine, palmatine, epiberberine and magnoflorine) could inhibit adipocyte differentiation and cellular triglyceride accumulation in 3T3-L1 cells, and downregulated adipocyte marker genes [including PPAR-γ and CCAAT/enhancer binding protein (C/EBP)I (Choi et al. 2014, 2015; Zhang et al. 2015)]. Lipolysis is the process of breaking down lipids and has been regarded as a target for treating obesity. Adiponectin, which is involved in the regulation of metabolic processes, binds to two main receptors (AdipoR1 and AdipoR2), whose expression levels are decreased during the development of obesity. Berberine treatment upregulated the expression of AdipoR1 and AdipoR2, which consequently elevated adiponectin production and induced lipolysis. Berberine could also directly upregulate lipolysis-related genes such as those encoding LPL, PPARα, carnitine hydroxysterolperoxidase 3-kinase III (PI3KIII) (Wang HQ et al. 2017). The accumulation of foam cells in the subendothelial space is an indispensable step for the initiation and progression of AS. Berberine treatment could suppress foam cell formation, as well as the accumulation of lipid and cholesterol. The mechanism involves the activation of adenosine 5-monophosphate (AMP)-activated protein kinase (AMPK)-SIRT1-peroxisome proliferators-activated receptor γ2 (PPAR-γ) pathway and a decrease in ox-LDL uptake (Chi et al. 2014). Berberine can stabilize atherosclerotic plaques by inhibiting the expressions of matrix metalloproteinase 9 (MMP-9) and extracellular matrix metalloproteinase inducer (EMMPRIN) by suppressing activation of the p38 pathway (Huang et al. 2011).
Table 5. Protecting cardiovascular system related diseases effect.

| Pharmacological effects                  | Extract/compounds | Material or model                        | Mechanism                                                                 | Dose                | Reference          |
|-----------------------------------------|-------------------|-----------------------------------------|---------------------------------------------------------------------------|---------------------|--------------------|
| Lipid lowering effect                   | 8                 | High fat (HF) diet C57BL/6J mice         | Suppressing of lipogenesis and the enhancement of lipid oxidation in the liver | 100 mg/kg, 56 d    | (Yang et al. 2016) |
| Lipid lowering effect                   | 8                 | High fat and high cholesterol (HFHC) diet hamsters | Down-regulating the expression of HMGCR and up-regulating the expression of LDLR and CYP7A1 as well as promoting the excretion of TBA in the feces | 46.7 mg/kg, for 140 d | (He et al. 2016)   |
| Hypolipidemic Effect                    | 3, 1, 8, 4, 5, Total alkaloids of CR (TACR) | High fat and high cholesterol (HFHC) diet hamsters | Up-regulating LDLR and CYP7A1, down-regulating HMGCR | in vivo: 70.05 mg/kg, 28 d; in vitro: 5 µg/mL | (Kou et al. 2016) |
| Hypolipidemic Effect                    | 3, 1, 8, 4, 5, Total alkaloids of CR (TACR) | High fat and high cholesterol (HFHC) diet hamsters | Up-regulating cholesterol transport and bile acid synthesis, inhibiting cholesterol synthesis and lipoprotein assembly or secretion | 46.7 mg/kg, for 140 d | (He et al. 2016)   |
| Antihyperlipidemia                      | 4, 8, 1, 5, TACR  | Diabetic KK-Ay mice; HepG2 cell          | Up-regulating LDLR and CYP7A1                                             | 225 mg/kg, 40 d; in vitro: 5 µg/mL | (Ma et al. 2016)   |
| Antihypercholesterole                   | berbamine         | HC diet hamsters; HepG2 cell             | In vivo: 70.05 mg/kg, 28 d; in vitro: 5 µg/mL                             | (Kou et al. 2016)   |
| Antihyperlipidemia                      | 3, 1, 4, TACR     | High fat C57BL/6J mice                   | Modulating of the enterohepatic circulation of bile acids and cross-talk between the gut microbiota and the liver | 140 mg/kg, 35 d    | (He et al. 2017)   |
| Antihyperlipidemia                      | Ethanol extracts of CR, 1 | High fat diet C57BL/6J mice             | Decreasing degradation of dietary polysaccharides, lowering potential calorie intake, activating mitochondrial energy metabolism, regulating on gut microbes | 200 mg/kg, 42 d    | (Xie W et al. 2011) |
| Anti-adipogenic activity                | 1, 3, 4, 5, 30    | 3T3-L1 cells                            | Inhibiting activation of AMPK signaling pathways and NF-kappa B nuclear translocation | 380 mg/kg, 56 d    | (Wu et al. 2016)   |
| Anti-adipogenic effect                  | 5                 | 3T3-L1 cells                            | Supressing atherogenesis via stimulation of AMPK-dependent UCPI2 expression | 150 mg/kg, 84 d    | (Feng et al. 2017) |
| Suppressing adipocyte differentiation   | 1                 | 3T3-L1 cells                            | Inhibiting oxidation and inflammation cytokine expressions                | 150 mg/kg, 84 d    | (Feng et al. 2016) |
| Treating atherosclerosis and other chronic inflammatory disease | 3 ApoE(-/-) mice | Inhibiting activation of MAPK signaling pathways and NF-kappa B nuclear translocation | 150 mg/kg, 84 d    | (Feng et al. 2017) |
| Treating obesity                        | 1                 | High fat and high carbohydrate diet Wistar rats | Increasing the production of adiponectin and regulating the AMPK mechanism | 380 mg/kg, 56 d    | (Wu et al. 2016)   |
| Anti-atherosclerosis                    | 1                 | Apolipoprotein E-deficient mice          | Inhibiting oxidation and inflammation cytokine expressions                | 150 mg/kg, 84 d    | (Feng et al. 2016) |
| Suppressing atherogenesis               | 1                 | Western diet ApoE                      | Inhibiting activation of MAPK signaling pathways and NF-kappa B nuclear translocation | 150 mg/kg, 84 d    | (Feng et al. 2017) |
| Anti-atherosclerosis                    | 1                 | THP-1-derived macrophages               | Activating AMPK-SIRT1-PPAR-γ pathway and diminishing the uptake of ox-LDL | 14.9, 29.7, 59.5 mg/L | (Chi et al. 2014) |
| Against I/R injury                      | 1                 | THP-1 cells                             | Suppressing the activation of p38 pathway                                 | 5, 10, 25, 50 µM    | (Huang et al. 2011) |
| Against I/R injury                      | 1                 | T2DM Wistar rats exposed to I/R         | AMPK activation, Akt phosphorylation, and GSK3 inhibition in the nonischemic areas of the diabetic heart | 100 mg/kg, 7 d     | (Chang et al. 2016) |
| Alleviating cardiac I/R injury          | 1                 | I/R C57BL/6 mice, H9c2 myocytes,        | Supressing autophagy activation by decreasing the expression of SIRT1, BNI3, and Beclin-1-AMPK and p-mTORC2 (Ser2481) | 5 mg/kg, 10 mg/kg; in vitro: 5, 10, 20 µM | (Huang et al. 2015) |
| Anti- I/R injury                        | 1                 | I/R SD rats                             | Attenuating mitochondrial dysfunction and myocardial apoptosis            | 200 mg/kg, 28 d    | (Wang Y et al. 2015) |
| Anti- I/R injury                        | 1                 | I/R SD rats, SIR H9c2 cells             | Modulating Notch1/Hes1-PTEN/Akt signaling                                | in vivo: 200 mg/kg, 14 d; in vitro: 50 µM | (Yu et al. 2015)   |
| Anti- I/R injury                        | 1                 | I/R SD rats, SIR H9c2 cells             | Activating the JAK2/STAT3 signaling pathway and attenuating ER stress-induced apoptosis | in vivo: 200 mg/kg, 50 d | (Zhao et al. 2016) |

(continued)
| Pharmacological effects              | Extract/compounds | Material or model                  | Mechanism                                                                 | Dose                                | Reference |
|-------------------------------------|-------------------|------------------------------------|---------------------------------------------------------------------------|-------------------------------------|-----------|
| Anti-I/R injury                     | 1                 | I/R SD rats                        | Suppressing the activation of PI3K/AKT signaling, Inhibiting apoptosis through the activation of Smad7 | 100 mg/kg, 14 d 50 μM              | (Zhu and Li 2016) |
| Anti-cardiac I/R injury             | 1                 | H/R H9c2 cells                     | Inhibiting apoptosis through the activation of Smad7                     | 5, 10 or 25 μM                     | (Yao et al. 2017) |
| Inhibition of autophagy induced by hypoxia | 1                | H9c2 cells under hypoxia           | Reducing oxidative damage and inflammation response, and SIRT1 signaling plays a key role in the regulation of AMPK | in vivo: 200 mg/kg, 14 d; in vitro: 50 μM | (Yu et al. 2016) |
| Attenuating MI/R injury             | 1                 | I/R SD rats, SI/R H9c2             | Activating the PPARY/NO signaling pathway                               | 0.01-0.1 μM.                       | (Jia et al. 2017) |
| Anti-hyper trophy                   | 1                 | High glucose-and insulin-induced cardiomyocyte | Anti-inflammatory and antioxidative activity through regulating HMGB1-TLR4 Axis | 30, 60 mg/kg, 14 d                 | (Zhang M et al. 2013) |
| Anti-acute myocardial ischemia      | 3                 | H/R H9c2 cell                      | Inhibition of autophagy                                                  | 0.3, 1, 3, 10 μM                   | (Wang Y et al. 2017) |
| Anti-I/R injury                     | 3                 | I/R SD rats                        | Suppressing myocardial autophagy and inflammation by inhibiting the Rho/ROCK pathway | 3, 10, and 30 mg/kg                | (Guo et al. 2013) |
| Reducing I/R injury                 | 4                 | I/R SD rats, HAEC cells, RAW 264.7 cells | Reducing oxidative stress and modulating inflammatory mediators | in vivo: 25, 50 mg/kg; in vitro: 1, 2, 5, 10 μM in HAEC; 1, 5, 10 μM in RAW 264.7 cells | (Kim et al. 2009) |
| Anti-nonalcoholic steatohepatitis   | 1                 | HF diet Bal/c mice                 | Normalizing gut microbiota, decreasing expression of endotoxin receptor, inflammatory cytokines | 200 mg/kg, 56 d                    | (Cao et al. 2016) |
| Decreasing hepatic steatosis        | 1                 | HF C57BL/6J mice, H4IE cells       | Anti-inflammation                                                         | in vivo: 100 mg/kg, 28 d; in vitro: 10, 25, 50 μM | (Guo et al. 2016) |
| Attenuating hepatic steatosis       | 1                 | High fat and high-sucrose C57BL/6 mice, mouse primary hepatocytes, HepG2 cells | Inducing autophagy and fibroblast growth factor 21 in SIRT1-dependent manner | in vivo: 5 mg/kg, ip., 35 d; in vitro: 10 μM | (Sun et al. 2017) |
| Attenuating hepatic steatosis       | 1                 | HF diet SD rats, Huh7 cells        | Global modulation of hepatic mRNA and lncRNA expression profiles         | in vivo: 200 mg/kg, 112 d; in vitro: 10 μM | (Yuan et al. 2015) |
| Attenuating hepatic steatosis       | 1                 | Db/db mice and methionine-choline-deficient diet mice, tunicamycin-induced mice, HepG2 cells | Reducing endoplasmic reticulum stress through the ATF6/IRE1 pathway       | in vivo: 200 mg/kg, 35 or 20 or 3 d respectively; in vitro: 5 μM | (Zhang et al. 2016) |
Nonalcoholic fatty liver disease is a type of hepatic steatosis, which is always involved in obesity. It was reported that mice gut microbiota could be restored by gavage of 200 mg/kg of berberine for 8 weeks, resulting in alleviation of the predisposing factors for liver steatosis. These effects could be mediated by decreasing endotoxin receptor CD14 and inflammatory cytokines such as interleukin (IL)-1, IL-6, and tumour necrosis factor alpha (TNF-α) (Cao et al. 2016). This finding is consistent with another study that suggested that berberine’s actions are largely based on suppressing inflammation, independent of AMPK (Guo et al. 2016). Berberine could also attenuate hepatic steatosis and enhance energy expenditure in mice by inducing autophagy and fibroblast growth factor 21 (FGF21) expression; however, these effects were abolished by a deficiency of the nutrient sensor SIRT1 (Sun et al. 2017). Furthermore, increasing evidence suggests that the mechanism may correlate with global modulation of hepatic mRNA and long noncoding RNA (lncRNA) expression profiles, reducing endoplasmic reticulum stress (ER) stress through the ATF6/SREBP-1c pathway (Yuan et al. 2015; Zhang et al. 2016).

### Protective effect against ischaemic heart disease

Cardiac ischemia is characterized by the deficient supply of blood flow and energy generating nutrients to the myocardium (Steenbergen and Frangogiannis 2012). The most effective treatment for ischaemic heart disease (IHD) is to re-perfuse the heart. However, re-perfusion could lead to series of additional injuries, termed ischaemia reperfusion injury (IRI) (Wijck and Buurman 2002). CR and its active compounds could reduce apoptosis, excessive autophagy, and inflammatory response, regulate energy metabolism, improve mitochondrial function, as well as alleviate ER stress, all of which might combine to alleviate IRI.

Berberine treatment could improve myocardial infarction and injury to cardiomyocytes, as indicated by the decrease of creatine kinase isoenzyme (CK-MB), lactate dehydrogenase (LDH), and cardiac troponin (cTnI); reducing oxidative stress by suppressing malondialdehyde (MDA) production; and promoting superoxide dismutase (SOD) (Liu XT et al. 2010; Zhang T et al. 2014; Wang Y et al. 2015). In vivo and in vitro experiments showed that berberine could reduce the myocardial infarct size, improve cardiac function; and suppress myocardial apoptosis, oxidative damage, and ER stress through activating the JAK2/STAT3 signalling pathway (Zhao et al. 2016). Activation of the AMPK signalling pathway and silent information regulator 1 (SIRT1) signalling might be involved in the anti-autophagy and anti-apoptosis effect of berberine (Yu et al. 2016; Jia et al. 2017).

In pressure-overload-induced cardiac hypertrophy, berberine inhibited the mTOR, p38, and ERK1/2 MAPK signalling pathways to enhance autophagy, consequently attenuating left ventricular remodeling and cardiomyocyte apoptosis (Li MH et al. 2014). However, excessive autophagy activity can also cause cell death, termed ‘autophagic cell death’, also known as type-II programmed cell death (Li S et al. 2017). It has been reported that berberine could reduce excessive autophagy by suppressing autophagy-related proteins, such as LC3-II, SIRT1, BNIP3 and Beclin-1, thus protecting H9c2 cells from hypoxia/reoxygenization (HR)-induced cell death (Huang et al. 2015). In non-ischemic areas of diabetic animal hearts, berberine increased myocardial glucose uptake, glycolysis, and fatty acid oxidation (Chang et al. 2016). The observation that berberine could act as an M2 muscarinic agonist, which reduced the spontaneous contraction rate of cardiomyocytes in culture might contribute to our understanding of berberine’s complex actions on the heart (Salehi and Filtz 2011).

Studies have shown the berberine could reduce the release of TNF-α, IL-6, IL-β and HMGB1 to attenuate ischemic heart injury. TLR4, which is activated by HMGB1, is also reduced by berberine (Zhang T et al. 2014). Preconditioning with berberine for 14 days before the induction of I/R significantly attenuated myocardial I/R injury, as explained in the incidence of ventricular arrhythmia and the amelioration of myocardial histological changes. These effects were associated with the suppression of the PI3K/AKT signalling pathway and subsequent reduction of the expression of related inflammatory cytokines in the serum and myocardial tissue (Zhu and Li 2016).

Berberine could inhibit high glucose and insulin-induced cardiomyocyte hypertrophy, accompanied by increasing nitric oxide synthase (NOS) activity and NO concentration, which elevated PPARγ and eNOS (Wang M et al. 2013). Coptisine also has an effect against myocardial ischemia reperfusion (MI/R) injury by suppressing myocardial apoptosis and inflammation via inhibition of the Rho/ROCK pathway, and inhibiting autophagosomal formation rather than induction of autolysosomes in autophagy events (Guo et al. 2013; Wang Y et al. 2017).

Maintenance of mitochondrial integrity is one of the critical aspects of protecting the myocardium (Calo et al. 2013). Berberine could improve mitochondrial dysfunction, as indicated by increasing mitochondrial membrane potential, mitochondrial complex activity and decreasing the release of cytochrome C from mitochondria (Wang Y et al. 2015).

### Antidiabetes

Diabetes mellitus (DM) is a common chronic diseases characterized by disorders of glucose metabolism that seriously threaten human health and longevity (Shi and Hu 2014). As early as the Wei and Jin Dynasties, Ming Yi Bie Lu recorded the treatment of CR for Xiaoke, which has been proven to be DM. CR and its components exert anti-diabetic effects by improving glucose metabolism, insulin resistance (IR), pancreatic beta cells and modulating the gut microbiota (Table 6).

#### Improving glucose metabolism

The expression of the glucose transporter protein (GLUT) is a key factor in the intracellular transport of glucose and is closely linked to cellular energy metabolism (Huang 2013). A previous report revealed that after treatment with berberine, the glucose uptake in L929 fibroblast cells, a cell line that express only GLUT1, reached maximum stimulation. Moreover, significant activation was observed within 5 min and reached a maximum at 30 min, which was attributed to the acute activation of the transport activity of GLUT1 (Cok et al. 2011). The level of GLUT1 protein was increased in 3T3-L1 cells, which was stated to be associated with the activation of AMPK stimulation (Kim et al. 2007). The upregulation of GLUT4 expression and downregulation of Retinol-binding protein 4 (RBP4) are also involved in glucose uptake (Zhang et al. 2008). HepG2 and βTC3 cell lines were used to test glucose consumption and insulin release, respectively. The results showed that glucose consumption by HepG2 cells was increased from 32% to 60% by berberine, which was insulin independent but had no influence on insulin secretion (Xie et al. 2011). Another study showed the GnRH-
glucagon-like peptide-1 (GLP-1) and MAPK pathways in the intestines might be involved in the mechanisms of berberine to modulate glucose metabolism (Zhang Q et al. 2014).

**Improving insulin resistance**

Insulin resistance (IR) is a pathological condition in which cells fail to respond to the normal actions of the hormone insulin. IR increases the risk of developing pre-diabetes and type-2 DM. Treatment with berberine at 50 mg/kg/day for 2 weeks was effective against the features of IR syndrome, and could improve levels of IR parameters, such as body weight, hyperglycemia, hyperinsulinemia, hypercholesterolemia, and hypertriglyceridemia (Ye et al. 2016). Shen et al. (2012) revealed that berberine could decrease insulin levels in pancreatic islet β-cells via reversible the concentration-dependent inhibition of the INS2 promoter. Increasing the expression of insulin receptor (INSR) is also regarded as a target of berberine to increase insulin sensitivity. This effect is related to a protein kinase C (PKC)-dependent activation of its promoter (Kong WJ et al. 2009). In some insulin-resistant patients with diabetes, there is a phenomenon of increased IRS2 dephosphorylation by protein tyrosine phosphatase 1B (PTP1B). Interestingly, berberine can suppress the activation of PTP1B to increase the phosphorylation of INSR (Chen et al. 2010).

**Antidiabetes effect.**

| Pharmacological effects | Extract/compounds | Material or mode | Mechanism | Dose | Reference |
|------------------------|-------------------|-----------------|-----------|------|-----------|
| Antihyperglycemia      | 1, 3, 4, 5, 8     | Diabetic KK-Ay Mice; HepG2 cells          | Not mentioned | in vivo: 225 mg/kg, 40 d; in vitro: 5 μg/mL | (Ma et al. 2016) |
| Lowering glucose       | 1                 | HepG2 cells and betaTC3 cells             | insulin independent but has no effect on insulin secretion | 5 to 200 μM | (Xie X et al. 2011) |
| concentration          | 1                 | 3T3-L1 adipocytes                          | Activating GLUT1 through AMPK stimulation | 1, 5 μM | (Kim et al. 2007) |
| Activating glucose      | 1                 | C57BL/6J mice, NIT-1 cells                 | Inhibiting mouse insulin gene promoter through activation of AMPK and exerting beneficial effect on pancreatic β-cell | in vivo: 50 mg/kg, 70 d; in vitro: 0.01-10 μM | (Shen et al. 2012) |
| uptake                 | 1                 | RAW264.7 microphages                        | Through PKC-dependent up-regulation of insulin receptor expression | in vivo: 150, 300 mg/kg, 15 d, 200 mg/kg, 21 d; in vitro: 22.3 μM | (Kong WJ et al. 2009) |
| Treating 2 DM          | 1                 | Wistar rats, Caco-2 cells                  | Hypoglycemic effect, modulating enzymes and scavenging free radicals | 100, 200 mg/kg, 21 d | (Tang et al. 2006) |
| Antihyperglycemic       | 1                 | C57BL/6J mice, db/db mice, 3T3-L1 and L6 cells | Inhibiting PTP1B activity and mimicking insulin action | 100 mg/kg, 14 d; in vitro: 1.25-100 μM | (Chen et al. 2010) |
| Increasing glucose      | 1                 | Insulin-sensitive and insulin-resistant rat skeletal muscle cells | Improving tyrosine-phosphorylation of IRS-1 and the recruitment of p85 to IRS-1, PKC and PKB activity, inhibiting mTOR | 14.8 μM | (Liu LZ et al. 2010) |
| uptake                 | 1                 | Alloxan-induced Wistar rats                | Hypoglycemic effect, modulating enzymes and scavenging free radicals | 100, 200 mg/kg, 21 d | (Tang et al. 2006) |
| Insulinotropic effect   | 1                 | Primary rat islets                         | Activating HNF4α and GK | 1, 3, 10 and 30 μM | (Wang et al. 2008) |
| Treating T1DM          | 1                 | Nonobese diabetic (NOD) mice              | Protecting pancreatic islets and serum lipids | 50, 150, 500 mg/kg, 98 d | (Chueh & Lin 2011) |
| Protecting pancreatic  | 1                 | STZ-treated primary pancreatic islet cells | Down-regulating Bax/Bcl-2 gene expression ratio | 1, 3, 5 μM | (Chueh & Lin 2011) |
| islets                 | 1                 | HF diet and STZ induced rats               | Lowering RBP4 levels and up-regulating the expression of GLUT4 protein in tissues | 350 mg/kg, 28 d | (Zhang et al. 2008) |
| Treating T2DM          | 1                 | SD rats, NCI-H716 cells                    | Promoting GLP-1 secretion and GLP-1 biosynthesis in PKC-dependent pathway | in vivo: 60, 120 mg/kg, 35 d; in vitro: 1, 10, 100 μM | (Yu Y et al. 2010) |
| Antidiabetic effects   | 1                 | HepG2 cells                                | Improving insulin sensitivity via its anti-inflammatory activity | 0.1, 1, 10 μM | (Lou et al. 2011) |
| Ameliorating insulin   | 1                 | RAW264.7 microphages                        | Attenuating inflammation by SIRT1 | 5 μM | (Chuan 2016) |
| resistance             | 1                 | STZ induced ddY mice                       | Antioxidative stress via down regulating GPx and up-regulating CuZn-SOD | 200 mg/kg, 14 d | (Lao-Ong et al. 2012) |
| Treating T2DM          | 1                 | high-carbohydrate/high-fat diet Wistar rats | Antioxidation and up-regulating P-TEFb expression | 75, 150, 300 mg/kg, 42 d | (Zhou and Zhou 2011) |
| Treating T2DM          | 1                 | SH-SYSY cells                              | As an NF2 activator | 0.1-10 nM | (Hsu et al. 2013) |
| Hypoglycemic           | 1                 | STZ induced diabetic SD rats, Caco-2 cells | Suppressing disaccharidase activity and the mRNA expression of SII complex in PKA-dependent pathway | in vivo: 100, 200 mg/kg, 35 d; in vitro: 2, 10, 50 μM | (Liu et al. 2010) |
| Moderating glucose     | 1                 | HF diet SD rats                            | Regulating the MAPK and Gnrh receptor pathways in the ileum | 120, 240 mg/kg, 56 d | (Zhang Q et al. 2014) |

**Table 6. Antidiabetes effect.**
signalling. In insulin signalling, the levels of phosphorylated AKT and IRS were significantly increased by berberine in alloxaan-induced diabetic mice (Xie X et al. 2011). In insulin-resistant cells, berberine improved insulin-induced tyrosine-phosphorylation of IRS-1 and the recruitment of p85 to IRS-1, which was related to the inhibition of mTOR (Liu LZ et al. 2010).

**Improving pancreatic β cells and promoting the secretion of insulin**

Some studies reported that berberine could promote the secretion of insulin by increasing GLP-1 release or by stimulating pancreatic cells (Wang et al. 2008; Yu Y et al. 2010). Intragastric administration of berberine restored the damage to pancreas tissues and reversed the decreased in the number of islets in rats with DM (Tang et al. 2006; Chueh and Lin 2011). Berberine significantly downregulated the ratio of BAX/BCL-2 to block streptozotocin (STZ)-induced apoptosis in mouse pancreatic islets (Chueh and Lin 2012). Berberine and CRE exerted similar protective effect on islet β cells by improving islet β cell proliferation and the protein level of PARP1 (Jiang et al. 2017). Inflammation and oxidation are closely associated with DM. After treatment with berberine, decrease levels of proinflammatory cytokines, such as TNF-α, IL-6, iNOS, MCP-1 and COX-2, were observed (Jeong et al. 2009; Lou et al. 2011), while IL-10 levels were elevated in diabetic animals, in related cells, and in patients (Sun 2017). The levels of AR, SOD, GSH-px and GSH increased, while MDA decreased, indicating that oxidation was inhibited (Zhou and Zhou 2011; Lao-Ong et al. 2012). Multiple cellular kinases, as well as signalling pathways (such as MAPKs, AMPK, Nr2f2/HO, NF-κB, and Rho GTPase pathways) were verified to be pivotal for berberine’s activity in reducing oxidative stress and inflammation to treat DM (Wang et al. 2009; Xie et al. 2013; Mo et al. 2014). However, some studies showed that berberine could decrease hyperglycaemia and improve impaired glucose tolerance but did not increase insulin release and synthesis (Yin et al. 2002; Chen et al. 2010). In addition to berberine, recent studies showed that polysaccharides in CR increased glucose uptake, recovered glucose tolerance, inhibited the formation of advanced glycation end products, and reduced oxidation (Jiang et al. 2015; Cui et al. 2016; Yang Y et al. 2016).

**Modulating gut microbiota**

In recent years, berberine has been demonstrated to treat DM by modulating the structure and diversity of gut microbiota, including enrichment of beneficial microbes and inhibition of harmful microbes (Liu L et al. 2010). The bioavailability of berberine is very low, and the absorption rate is only 5–10% in the intestinal tract. However, it can significantly reduce the activity of disaccharidase and α-glucosidase in the intestinal tract, resulting in a reduction the absorption of glucose and postprandial hyperglycemia (Liu L et al. 2010; Li ZQ et al. 2012). CR alkaloid treatment avoided a decline in the diversity of gut microbes in obese mice and favoured the maintenance of a stable and healthy bacterial community in high-fat high cholesterol (HFFHC)-fed animals (Kai 2017). Berberine can lead to an increase in the abundance of probiotics such as *Blautia*, *Bacteroides*, *Bifidobacteria* and *Lactobacillus*, and a decrease in relative abundance of *Firmicutes* and *Bacteroides* in the intestinal tract of animals (Meng et al. 2016; Gu et al. 2017).

Another study showed that the berberine selectively enriched the propionic acid producing bacteria and intestinal barrier repair bacteria Ackermania; a CR decoction promoted butyric acid producing bacteria, such as *Coprococcus*, *Faecalis bacteria* and *Oscillospora*. Compared with berberine, the CR decoction induced higher flora diversity, and the flora structure was closer to that of normal animals (Ti 2017). The increase of GLP-1 and short-chain fatty acids in the gut may account for the structural and diversity changes to the microbiota induced by berberine (Sun et al. 2016).

**Anticancer effect**

Cancer is the second leading cause of death globally and was responsible for 8.8 million deaths in 2015. Globally, nearly 1 in 6 deaths are caused by cancer, as reported by the World Health Organization. Studies showed that CR and berberine are effective against multiple types of human cancer, including bladder, breast, cervix, cholangiocarcinoma, colon, Ehrlich, gastric, glioma, intestine, kidney, leukemia, liver, lung, nasopharyngeal, melanoma, myeloma, ovary, pancreas, prostate and sarcoma (Ho et al. 2009; Wang N et al. 2015). CR and its active ingredients can prevent cancer by blocking the cell cycle, inhibiting tumor cell proliferation, inducing apoptosis, inhibiting migration and invasion, and enhancing the body’s immune function (Table 7).

**Inducing apoptosis**

Berberine induces apoptosis in human colonic carcinoma cell line SW620; in the pancreatic cancer cell lines PANC-1 and MIA-PaCa2; and in breast cancer MCF-7 cells through the generation of ROS. Moreover, berberine had a greater apoptotic effect in PANC-1 cells than gemcitabine (Hsu et al. 2007; Xie et al. 2012; Park et al. 2015). When compared with chemical drugs (meloxicam and rosiglitazone) and berberine, total alkaloids showed a greater apoptosis-inducing effect (Ke 2007). Various apoptotic modulating signals are involved the induction of apoptosis by berberine. Berberine could markedly inhibit the expression of survivin in MGC-803gastric cancer cells, in SKOV3ovarian cancer cells (Zhang et al. 2013; Ma et al. 2015); and activated caspase-3, caspase-8, caspase-7 and caspase-9 in FaDu head and neck squamous cell carcinoma cells and malignant pleural mesothelioma (Yao 2014; Seo et al. 2015). Berberine also regulated the activities of Bcl-2 and Bax in colon cancer cells (Chidambara et al. 2012), FoxO1 and FoxO3 in HepG2 cells (Shukla et al. 2014), and p53 in MCF-7 and MDA-MB231breast cancer cells (Kim et al. 2012). Additionally, cPLA-COX2 and JAK2/STAT3 signalling was inhibited in liver cancer cells and colon cancer cells HT-29 (Li O et al. 2013; Li C et al. 2014). Berberine also promoted the Fas/FasL signalling pathway, and then triggered the activation of caspase-8 and caspase-9 precursors to induce apoptosis in human oral cancer cells (Kim et al. 2015). In HCT-116 colon cancer cells, berberine enhanced GRP78 activity by binding to and forming complexes with GRP78, which increased the ability of GRP78 to bind to VPS34. This suggested berberine could induce autophagic cancer cell death (La et al. 2017). In vitro and in vivo experiments showed that coptisine inhibited the proliferation, growth and migration of HCC cells and colorectal cancer cells, and promoted their apoptosis. Other studies showed that coptisine activated microRNA miR-122 (Chai et al. 2018) and the 67-kDa Laminin Receptor (Zhou et al. 2018), and inhibited MFG-E8 (Cao et al. 2018).
| Pharmacological effects | Material or model | Mechanism | Dose | Reference |
|-------------------------|------------------|-----------|------|-----------|
| Treating melanoma       | A375 cells       | Up-regulating p38 MAPK, GR and down-regulating DHODH | 5, 10, 20, 40, 80 μM | (Liu B et al. 2017) |
| Treating melanoma       | B16 cells        | Modulating the PI3K/Akt pathway, RARα/ RARβ expression | 10, 20, 40 μM | (Kou et al. 2016) |
| Treating hepatocellular carcinoma | HepG2 cells | Promoting apoptosis through the NF-κB p65 pathway | 10, 50, 100 μM | (Li M et al. 2017) |
| Treating hepatocellular carcinoma | HepG2 cells, MHCC97-L and HepG2 cells xenograft mice | Suppressing vascular endothelial growth factor via inactivation of eukaryotic elongation factor 2 | in vitro: IC_{50} of 500 and 150 μg/mL at 24 and 48 h in MHCC97L cells, 250 and 120 μg/mL in HepG2 cells; in vivo: 50 mg/kg/2 d, 21 d | (Tan et al. 2014) |
| Treating hepatocellular carcinoma | MHCC97-L cells | Downregulating the Rho/ROCK signaling pathway | 300, 150 μM at 24 h and 48 h | (Wang N et al. 2010) |
| Treating hepatocellular carcinoma | HepG2 and MHCC97-L cells | Increasing Bax expression, activating Beclin-1, inhibiting mTOR-signaling pathway by suppressing the activity of Akt and up-regulating P38 MAPK signaling | IC_{50}: 100 μM in HepG2 cells, 250 μM in MHCC97-L cells | |
| Treating hepatocellular carcinoma | berberine hydrochloride | AMPK activation | 50, 100 μM | (Yu et al. 2014) |
| Treating hepatocellular carcinoma | SMMC7721 xenograft mice, SMMC7721 and HepG2 cells | Induction of apoptosis through a 67LR/cGMP pathway | in vivo: 50 mg/kg; in vitro: 12.5, 25, 50,100 μM | (Zhang et al. 2018) |
| Treating glioma | Coptis Chinensis granules | Down-regulating phosphorylation of STAT3 by reducing HDAC3 | in vivo: 20, 10 mg/per mouse, 1 month at intervals of 1 d; in vitro: 0.625, 1.25, 2.5, 5 or 10 mg/mL; | (La et al. 2017) |
| Inducing autophagic cell death | HCT-116, HepG2, DLD1 cells | Enhancing GRP78 levels and The ability of GRP78 to bind to VPS34 | IC_{50} 80, 100, 200 μM in HCT-116, HepG2, DLD1 respectively | |
| Treating osteosarcoma | Xenograft mice, Saso-2 and MG-63 cells | Downregulating caspase-1/IL-1β inflammatory signaling | in vivo: 20 mg/kg, 21 d; in vitro: 50 μM | (Jin et al. 2016) |
| Treating osteosarcoma | MG-63 cells, SW1353, Saso-2, and U-2OS cells | Inducing apoptosis and DNA damage | 20, 40, 60, 80 μM | (Zhu et al. 2014) |
| Treating esophageal cancer | KYSE-30 cells | Anti-migration and anti-metastasis mediated by chemokine receptors | IC_{50} 60, 45 and 40 μM after 24, 48 and 72 h, respectively | (Mishan et al. 2015) |
| Treating lung cancer | H460, H1975 cells | Suppressing both phosphorylated and total levels of STAT3 protein and promoting STAT3 degradation by enhancing ubiquitination | IC_{50} 13.4 and 62.43 μM for H460 and H1975 cells | (Zhu et al. 2015) |
| Treating human gastric cancer | Xenograft nude mice, BGC-823 and SGC7901 cells | Inhibiting the Akt/mTOR/p70S6/S6 pathway | in vivo: 10 mg/kg injected intratumorally once every 3 d for 18 d in vitro: 10, 25, 50, 75, 100 μM | (Yi et al. 2015) |
| Treating breast cancer | MDA-MB-231 cells | Anti-metastatic function through down-regulation of MMP-9 in combination with the increase of TIMP-1 | 16, 32, 64 μM | (Li J et al. 2014) |
| Treating nasopharyngeal carcinoma | berberine hydrochloride | Blocking proliferation, migration and invasion, and inducing apoptosis | IC_{50} 31.5 μM | (Li CH et al. 2014) |
| Treating tongue squamous cancer | SCC-4 cells | Inhibiting FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9 | 62.5, 125 μM | (Ho et al. 2009) |
| Treating human colon cancer | SW620 cells | | 50 μM | (Hsu et al. 2007) |
Cell cycle arrest

Berberine inhibited the expression of Cyclin D1 and the activity of the related AP-1 and Wnt pathways. Berberine prevented the proliferation of lung cancer PG cells by inhibiting Cyclin D1, increasing the number of cells in the G0/G1 phase, and decreasing the number of cells in the S phase and G2/M phase (Ye 2007). Berberine blocked human gastric carcinoma cell entrance into the cell cycle in the G0/G1 phase, and inhibited colorectal adenocarcinoma growth by inducing G2/M phase arrest (Sha et al. 2011; Cai et al. 2014). However, CR and berberine decreased the number of CNZ-2Z cells in the G0/G1 phase significantly, while the number of cells in the S phase increased significantly, indicating that the cell cycle was blocked in the S phase (Cui et al. 2008). In osteosarcoma, berberine treatment led to G1/S cell cycle arrest in p53-presenting cells, but may cause G2/M arrest in p53-deficient cells, suggesting that p53 may play diverse roles in the cell cycle distribution in berberine-treated cancer cells (Liu et al. 2009). In addition, another CR component, jatrorrhizine, could inhibit the proliferation and neovascularization of C8161 human metastatic melanoma cells by inducing cell cycle arrest at the G0/G1 transition (Liu et al. 2013). Moreover, columbamine could suppress proliferation and neovascularization of metastatic osteosarcoma U2OS cells with low cytotoxicity and induced cell cycle arrest at the G2/M transition, which was associated with attenuation of CDK6 gene expression, STAT3 phosphorylation and MMP2 expression (Bao et al. 2012).

Inhibiting tumour metastasis

Urokinase-type plasminogen activator (uPA) and MMPs play important roles in cancer metastasis and angiogenesis, and inhibition of uPA and MMP could inhibit the migration and invasion of cancer cells. Berberine affected JNK, ERK1/2, p38 MAPK, P13K-Akt and NF-κB signalling pathways to inhibit the actions of MMP-2, MMP-9, MMP-1, and uPA in SCC-4 human tongue squamous carcinoma cells, hepatoma cells, and breast cancer cells (Ho et al. 2009; Bing et al. 2011; Kim et al. 2012; Kuo et al. 2012). NM23-H1 and SDF-1 are potential genes associated with tumour cell metastasis and previous research indicated that berberine could decrease NM23-H1 and SDF-1 expression; thus reducing the metastasis of leukaemia cells (Li, Guo, et al. 2008; Liu et al. 2008). It was reported that berberine (50 μM) could act as a RhoGTPases inhibitor in HONE1 human nasopharyngeal carcinoma cell (Tang et al. 2009). Inhibition of RhoGTPase by CRE, as well as by berberine (100-200 μM), might also result in blockade of ROCK signalling in hepatoma cells (Wang et al. 2010). The expression levels of two chemokine receptors (CXCR4 and CCR7), which are involved in the migration and metastasis of esophageal cancer cells, were decreased following the berberine treatment (Mishan et al. 2015).

Tumour angiogenesis, a process associated with invasion and metastasis, is an essential link in the control of tumour progression (Zhao and Adjei 2015). In tumour angiogenesis, VEGF and hypoxia-inducible factor-1α (HIF-1α) play a key role in tumour progression. In vivo and in vitro studies revealed that the antiangiogenic activity of berberine was mediated by downregulating the expression of HIF-1, VEGF and proinflammatory mediators in hepatocellular carcinoma cells and breast cancer cells (Jie et al. 2011; Hamsa & Kuttan 2012; Kim et al. 2013). Berberine may also inhibit the adhesion of gastric cancer cells to endothelial cells by increasing the proportion of intercellular adhesion

---

### Table 7. Continued.

| Extract or compounds | Material or model | Mechanism | Material or model | Dose | Reference |
|----------------------|------------------|-----------|------------------|------|-----------|
| Coptidis Rhizoma, 1 | Xenograft mice, YES-2, YES-2 cells | Down-regulating tumor IL-6 production | Coptidis Rhizoma, 1 | Xenograft mice, YES-2, YES-2 cells | 8-32 mM |
| | | | | | (Iizuka et al. 2000) |
molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), thus reducing the risk of tumour angiogenesis induced by evodiamine (Shi et al. 2013). In addition, berberine showed anti-angiogenesis effects on animals that were orthotopically implanted with hepatocellular carcinoma (Tsang et al. 2015). Coptisine at 150 mg/kg may reduce cancer metastasis risk by inhibiting the RAS-ERK pathway in HCT116 bearing mice (Huang et al. 2017). Coptisine at 150 mg/kg may reduce cancer metastasis risk in animals that were orthotopically implanted with hepatocellular carcinoma (Tsang et al. 2015). Coptisine at 150 mg/kg may reduce cancer metastasis risk by inhibiting the RAS-ERK pathway in HCT116 bearing mice (Huang et al. 2017).

Chinese medicinal herbs can enhance the body’s immune function, by inducing cytokines, interferon (IFN), lymphocyte-activated killer cells production and natural killer (NK) cell proliferation, thereby mediating tumor cell apoptosis. Importantly, CRE could markedly increase the IFN-β and TNF-α mRNA expression in breast cancer MCF-7 oestrogen receptor-positive cells (Kang et al. 2005) Furthermore, berberine was also capable of reducing the expression of caspase-1 and IL-1β in osteosarcoma cells, and inhibiting the growth of tumour cells, suggesting that the mechanism might involve downregulation of the caspase-1/IL-1β inflammatory signalling axis (Jin et al. 2016). A recent study showed that palmitate disrupted the interaction between pancreatic stellate cells and cancer cells in the tumour microenvironment, consequently resulting in the inhibition of cancer growth and migration, while inducing apoptosis by inhibiting survivin (Chakravarthy et al. 2018).

**Other pharmacological effects**

Experimental studies showed that CR and its compounds could be used to treat diseases of nervous system, digestive system, skeleton, and skin and hepatotoxicity, nephrotoxicity and aging-related disorders (Lee et al. 2010; Su et al. 2017). Berberine could ameliorate β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer’s disease transgenic mouse model through the PI3K/AKT/GSK3 signalling pathway and induced 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme-oxygenase-1 and exert antidepressant action through inhibition of organic cation transporter 2 and 3 (Durairajan et al. 2012; Bae et al. 2013; Sun et al. 2014). Furthermore, CRE could treat Alzheimer’s disease via the significant inhibition of acetylcholinesterase (AChE) (Kaufmann et al. 2016). CRE, coptisine and jatrorrizine displayed neuroprotective effect by alleviating oxidative stress (Friedemann et al. 2015, 2016; Luo et al. 2016). Berberine prevented glucocorticoid-induced bone loss in lumbar spongy bone by promoting bone formation and inhibiting bone resorption (Bilian et al. 2011). CRE had a radioprotective effect against radiation-induced skin damage in rats by modulating oxidative stress in skin and in aging-related diseases via antioxidation and AMPK activation (Wang XJ et al. 2013; Xu Z et al. 2017). In the digestive system, CRE extracts could exert an analgesic effect on a rat model of irritable bowel syndrome by decreasing serotonin release and cholecystokinin expression (Tjong et al. 2011). Coptisine showed a significant gastric mucosal protective effect on stress gastric ulcers in mice. However, the protective effect of coptisine (57 mg/kg) on the gastric mucosa was significantly better than that of 100 mg/kg berberine (Feng et al. 2007). Jatrorrizine delayed gastric emptying and intestinal transit in postoperative ileus (Zhang et al. 2012). Berberine has the potential to alleviate premenopausal syndrome by decreasing oxidative stress, LDL, triglycerides, insulin resistance and improving mood (Caliceti et al. 2015).

**Pharmacokinetics**

Currently, pharmacokinetics research on CR has mainly focused on the protoberberine alkaloids. After oral intake, blood exposure and absolute bioavailability are extremely low. During absorption, 50% of berberine undergoes extensive first-pass elimination (Liu Y et al. 2010). Then, the absorbed alkaloids are quickly and widely distributed in tissues, such as the brain, intestine, stomach, pancreas, heart, kidney, liver, spleen, lung, testicles and uterus, among which the liver has the highest concentration (Ma et al. 2010). Furthermore, the concentrations of the alkaloids in tissues are not only higher than those in circulation, but also are eliminated at a slower rate (Liu Y et al. 2010). Researchers have analysed metabolites from urine, feces, plasma, and intestinal flora and found that they mainly comprise the sulphate and glucuronide conjugates of the CR alkaloids or the Phase I metabolites of the alkaloids (Yang et al. 2010). In liver microsomes, cytochrome P450 isoenzymes (CYPs) play a major role. The intestinal flora also exerts significant effect on the enterohepatic circulation of the metabolites, which may be related to the multiple peaks phenomenon of the pharmacokinetics of the CR alkaloids (Zuo et al. 2006). Berberine is usually excreted in urine and bile. Other studies showed, only 0.013% of berberine is eliminated directly in urine after oral administration (Yu et al. 2000). The metabolites are mainly eliminated via urine (Yang et al. 2010), and a proportion of them are also eliminated through bile (Zuo et al. 2006). However, in some pathological conditions, such as diabetes mellitus, PI-IBS (post-inflammation irritable bowel syndrome) and lipopolysaccharide-related diseases, the pharmacokinetic processes are altered. In 2008, Yu et al. showed a higher exposure of berberine, palmitate, coptisine, epiberberine and jatrorrizine, with 170–330% increases in $C_{\text{max}}$ (maximum concentration) and 150–350% increases in AUC$_{0-24}$ (area under curve) in diabetic rats, after oral administration of CRE (1.3 g/kg). Then, in 2010, they discovered that impairment of the function and expression of P-glycoprotein in the intestine partly contributed to the increased exposure of the five protoberberine alkaloids (Yu et al. 2010).

After oral intake of berberine, the AUC$_{0-4}$ in mice with PI-IBS was higher than that in normal mice, while the total body clearance decreased significantly (Gong et al. 2014). In a pharmacokinetic study, magnoflorine showed lower bioavailability and faster absorption and elimination. However, pharmacokinetic parameters altered remarkably when magnoflorine was administered in a CR decoction. Oral gavage of a CR decoction decreased the absorption and elimination rates of magnoflorine, which revealed the pharmacokinetic interactions between magnoflorine and the rest of ingredients in CR (Xue B et al. 2015). Berberine in plasma was quickly eliminated after intravenous injection of CR; however, berberine could penetrate the blood-brain barrier (BBB) and reached the hippocampus with a rapid increase and slow elimination (Wang et al. 2005; Table 8).

**Toxicology**

CR has been banned in Singapore in recent decades because of the suggestion that berberine aggravated jaundice and kernicterus in neonates with glucose-6-phosphate dehydrogenase deficiency (Wong 1980). In 2012, researchers found no organ toxicity or electrolyte imbalance in 20 patients administered with CR at a daily dose of 3 g for 1055 patient-days (Linn et al. 2012). In 2016, the ban of Chinese herbal medicines rich in berberine was officially lifted. Nevertheless, toxicity cannot be ignored. An
| Subjects/animals                  | Drug administered | Dosages | Detected compounds | Pharmacokinetic parameters | References          |
|----------------------------------|-------------------|---------|--------------------|-----------------------------|----------------------|
| Male SD rats                     | TACR (i.g.)       | 1.3 g/kg| 1                  | AUC₀₋₂₄ (ng·h·mL⁻¹): 147.66 ± 14.19, | (Yu et al. 2007)    |
|                                  |                   |         |                    | Cₘₚₐₓ (ng·mL⁻¹): 11.39 ± 1.62, |                     |
|                                  |                   |         |                    | Tₘₚₐₓ (h): 3.40 ± 1.47,         |                     |
|                                  |                   |         |                    | MRT (h): 9.31 ± 0.81           |                     |
|                                  |                   |         |                    | AUC₀₋₂₄ (ng·h/mL): 11.74 ± 7.24, |                     |
|                                  |                   |         |                    | Cₘₚₐₓ (ng/mL): 1.52 ± 0.74,     |                     |
|                                  |                   |         |                    | Tₘₚₐₓ (h): 2.25 ± 1.82,         |                     |
|                                  |                   |         |                    | MRT (h): 6.69 ± 2.07           |                     |
|                                  |                   |         |                    | Cₘₚₐₓ (ng/mL): 0.84 ± 0.47,     |                     |
|                                  |                   |         |                    | Tₘₚₐₓ (h): 1.69 ± 1.72          |                     |
|                                  |                   |         |                    | MRT (h): 3.00 ± 0.95           |                     |
|                                  |                   |         |                    | AUC₀₋₂₄ (ng·h/mL): 10.19 ± 6.67,|                     |
|                                  |                   |         |                    | Cₘₚₐₓ (ng/mL): 2.40 ± 0.88,     |                     |
|                                  |                   |         |                    | Tₘₚₐₓ (h): 1.30 ± 1.56          |                     |
|                                  |                   |         |                    | MRT (h): 5.09 ± 2.44           |                     |
| Male diabetic SD rats            | CRE (i.g.)        | 1.3 g/kg| 1                  | AUC₀₋₂₄ (ng·h·mL⁻¹): 255.10 ± 8.04 | (Yu et al. 2008)  |
|                                  |                   |         |                    | Cₘₚₐₓ (ng/mL): 24.97 ± 8.39     |                     |
|                                  |                   |         |                    | Tₘₚₐₓ (h): 3.10 ± 1.52          |                     |
|                                  |                   |         |                    | MRT (h): 9.44 ± 1.52           |                     |
|                                  |                   |         |                    | AUC₀₋₂₄ (ng·h/mL): 35.53 ± 10.32|                     |
|                                  |                   |         |                    | Cₘₚₐₓ (ng/mL): 4.88 ± 1.40      |                     |
|                                  |                   |         |                    | Tₘₚₐₓ (h): 2.80 ± 1.44          |                     |
|                                  |                   |         |                    | MRT (h): 8.17 ± 1.30           |                     |
|                                  |                   |         |                    | AUC₀₋₂₄ (ng·h/mL): 35.97 ± 11.14|                     |
|                                  |                   |         |                    | Cₘₚₐₓ (ng/mL): 6.26 ± 2.37      |                     |
|                                  |                   |         |                    | Tₘₚₐₓ (h): 2.80 ± 1.44          |                     |
|                                  |                   |         |                    | MRT (h): 7.28 ± 1.71           |                     |
|                                  |                   |         |                    | AUC₀₋₂₄ (ng·h/mL): 8.17 ± 3.30  |                     |
|                                  |                   |         |                    | Cₘₚₐₓ (ng/mL): 1.30 ± 0.23      |                     |
|                                  |                   |         |                    | Tₘₚₐₓ (h): 3.00 ± 1.06          |                     |
|                                  |                   |         |                    | MRT (h): 6.84 ± 1.45           |                     |
|                                  |                   |         |                    | AUC₀₋₂₄ (ng·h/mL): 22.02 ± 4.39 |                     |
|                                  |                   |         |                    | Cₘₚₐₓ (ng/mL): 2.93 ± 1.14      |                     |
|                                  |                   |         |                    | Tₘₚₐₓ (h): 4.00 ± 3.79          |                     |
|                                  |                   |         |                    | MRT (h): 9.30 ± 0.61           |                     |
| Male pseudo germ-free Wistar rats| 1 (i.g.)          | 40 mg/kg| 1                  | AUC₀₋₄₈ (ng·h·mL⁻¹): 40.89     | (Zuo et al. 2006)  |
|                                  |                   |         |                    | Berberrubie,                 |                     |
|                                  |                   |         |                    | AUC₀₋₄₈ (ng·h/mL): 437.29      |                     |
|                                  |                   |         |                    | Thalifendine,                |                     |
|                                  |                   |         |                    | AUC₀₋₄₈ (ng·h/mL): 287.85      |                     |
|                                  |                   |         |                    | Emethylen-ebberberine        |                     |
|                                  |                   |         |                    | AUC₀₋₄₈ (ng·h/mL): 735.22      |                     |
|                                  |                   |         |                    | Mitt (h): 15.08               |                     |
|                                  |                   |         |                    | AUC₀₋₄₈ (ng·h/mL): 101.98      |                     |
|                                  |                   |         |                    | Mitt (h): 4.05                |                     |
| Male Wistar rats                 | 1 (i.g.)          | 40 mg/kg| 1                  | AUC₀₋₄₈ (ng·h·mL⁻¹): 1879.64, |                     |
|                                  |                   |         |                    | Berberrubie,                 |                     |
|                                  |                   |         |                    | AUC₀₋₄₈ (ng·h/mL): 37.42       |                     |
|                                  |                   |         |                    | Thalifendine,                |                     |
|                                  |                   |         |                    | AUC₀₋₄₈ (ng·h/mL): 811.05      |                     |
|                                  |                   |         |                    | Mitt (h): 18.32               |                     |
|                                  |                   |         |                    | Emethylen-ebberberine        |                     |
|                                  |                   |         |                    | AUC₀₋₄₈ (ng·h/mL): 1763.62,    |                     |
|                                  |                   |         |                    | Mitt (h): 24.68               |                     |
| Post inflammation irritable bowel syndrome male Wistar rats | berberine hydrochloride (i.g.) | 25 mg/kg | 1 | AUC₀₋₄₈ (ng·h·mL⁻¹): 2,763.43 ± 203.14 | (Gong et al. 2014) |
|                                  |                   |         |                    | Cₘₚₐₓ (ng·mL⁻¹): 18.53 ± 0.61  |                     |
|                                  |                   |         |                    | Tₘₚₐₓ (min): 15.00 ± 0.00       |                     |
|                                  |                   |         |                    | T₁/₂, kᵺ (min): 941.45 ± 60.39 |                     |
|                                  |                   |         |                    | VₚₑFₑ₂ (L/kg): 41,202.89 ± 4,112.68 |                     |
|                                  |                   |         |                    | CL/F (L/h/kg): 3,270.57 ± 58.32|                     |
| Male SD rats                     | berberine hydrochloride (i.g.) | 25 mg/kg | 1 | AUC₀₋₄₈ (ng·h·mL⁻¹): 2,039.49 ± 492.24 | (Sheng et al. 1993) |
|                                  |                   |         |                    | Cₘₚₐₓ (ng·mL⁻¹): 16.74 ± 4.47  |                     |
|                                  |                   |         |                    | Tₘₚₐₓ (min): 15.00 ± 0.00       |                     |
|                                  |                   |         |                    | T₁/₂, kᵺ (min): 770.36 ± 65.01 |                     |
|                                  |                   |         |                    | VₚₑFₑ₂ (L/kg): 60,036.51 ± 19,704.59 |                     |
|                                  |                   |         |                    | CL/F (L/h/kg): 4,999.34 ± 1,198.79 |                     |
| Male Beagle Dog                  | 1 (i.v.)          | 100 mg/kg| 1                  | AUC (mg·h/L): 1979.31 ± 1140.31| (Sheng et al. 1993) |
|                                  |                   |         |                    | Mitt (h): 10.28 ± 2.5          |                     |

(continued)
Table 8. Continued.

| Subjects/animals | Drug administered | Dosages | Detected compounds | Pharmacokinetic parameters | References |
|------------------|-------------------|---------|--------------------|---------------------------|------------|
|                  |                   |         |                    |                           |            |
| Male Wistar rats | CRE (i.g.)        | 1.2 g/kg| 1                  |                           | (Bao et al. 2010) |
|                  |                   |         |                    |                           |            |
|                  |                   | 2.4 g/kg| 1                  |                           |            |
|                  |                   |         |                    |                           |            |
|                  |                   | 4.8 g/kg| 1                  |                           |            |
| Male Wistar rats | CRE (i.v.)        | 10.2 mg/kg| 1                  |                           | (Wang et al. 2005) |
|                  |                   |         |                    |                           |            |
| Male healthy     |                   | 300 mg  | 1 (p.o.)           |                           | (Li & Zhang 1997) |
| volunteers       |                   | 300 mg  | 1                  |                           |            |
|                  |                   |         |                    |                           |            |
| Male Wistar rats | CRE (i.g.)        | 300 mg/kg| 1                  |                           | (Liu et al. 2014) |
|                  |                   |         |                    |                           |            |
|                  |                   |         |                    |                           |            |
|                  |                   |         |                    |                           |            |

Notes: AUC: area under curve; $C_{max}$: maximum concentration; CL: body clearance; i.g.: intragastric; i.v.: intravenous; MTT: mean transit time; p.o.: per os; $T_1/2$: half-life; $T_{1/2A}$: distribution half-life; $T_{1/2B}$: elimination half-life; $T_{1/2K}$: absorption half-life; $T_{max}$: time to peak concentration; Vd: volume of distribution.
modulation of the composition of the gut microbiota (enrichment of beneficial microbiota and inhibition of harmful microbiota) as one of the most important aspect for treating obesity, diabetes, and other metabolic disorders. As a natural compound with both anti-inflammatory and antitumor activities, berberine shows great potential in cancer treatment. However, the effects of berberine are not strong; therefore, structural modification of berberine is required. Moreover, CR containing various active components may be more effective than its single component berberine and could provide multiple therapeutic effects. There is a significant difference between the blood concentration and the tissue concentration. Therefore, to find a suitable pharmacokinetic marker for CR may be challenging but is necessary. Moreover, the pharmacokinetics of TCM should try to elucidate all the chemical components entering the body and their processes in the body (absorption, distribution, metabolism and excretion), with the aim of building a bridge between the complex chemical components and the systemic clinical effects, to reveal the underlying mechanism(s). Additionally, related target-organ toxicity evaluations are lacking. Thus, more work should be devoted to investigating the pharmacokinetics and features of CR and its active components, and further clinical studies are required to evaluate the potential curative effects and possible toxicities of CR and its active components toward the target organs. In addition, according to the current pharmacological research, berberine is not only the main active component but also the primary toxic component of CR. Consequently, it is crucial to develop a strategy to balance the pharmacological effects and toxicity of berberine. Besides, current reports on the original plants used to make CR, including C. chinensis, C. deltoidea and C. teeta, commonly focus on the chemical components and pharmacological effects of the roots because of their traditional use in TCM, and the other parts of the plants are often ignored and disposed of without pretreatment (Shen 2006). However, some previous reports revealed that the leaves of the CR plants also contain berberine (Li et al. 2004; Liu T et al. 2010). Therefore, further research is required to investigate the chemical constituents and pharmacological activities of the other parts of the original CR plants.

This present study systematically reviewed the traditional uses, botany, phytochemistry, pharmacology, and toxicology of CR to provide comprehensive information regarding this herbal medicine, which could be beneficial for highlighting the importance of CR and providing some clues for the future research of this herbal medicine.

**Future perspectives and conclusions**

Herbal medicines, including TCMs, are considered useful agents to treat various human diseases (Li et al. 2009; Peng et al. 2018). CR has a long history of being used as an important herbal medicine in Asian countries because of its reliable curative effects against various diseases. Nowadays, the most predominant traditional uses of CR have been confirmed by modern pharmacological research. So far, these investigations have reported that CR contains abundant isoquinoline alkaloids (especially berberine), which are also the active substances responsible for the pharmacological effects of this TCM. CR and berberine have a broad-spectrum antibacterial effect, manifesting as bacteriostasis at low concentrations and sterilization at high concentrations. This suggests that a combination of berberine or CR and conventional antibacterial drugs might exert a greater effect. Intensive research has indicated that CR has potential as a cardioprotective agent. In addition to reducing the incidence, it also protects the heart from MI/R injury. These properties are mainly attributed to berberine, coptisine, palmatine, epiberberine, jatrorrhizine and magnoflorine. Many studies have demonstrated modulation of the composition of the gut microbiota ( attributed to berberine, coptisine, palmatine, epiberberine, jatrorrhizine and magnoflorine. Many studies have demonstrated modulation of the composition of the gut microbiota
References

Ashraf MJ, Baswai P. 2013. Obesity: the ‘hug’ problem in cardiovascular diseases. Missouri Medicine. 110:699–594.

Bae J, Lee D, Yun KK, Gil M, Lee JY, Lee KJ. 2013. Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1. Mol Cells. 35:151–157.

Bao M, Cao Z, Yu D, Fu S, Zhang G, Yang P, Pan Y, Yang B, Han H, Zhou Q. 2012. Columbamine suppresses the proliferation and neovascularization of metastatic osteosarcoma U2OS cells with low cytotoxicity. Toxicol Lett. 215:174–180.

Bao TD, L YJ, Yang Q, Weng XG, Zhang YF, Dong Y, Wang YW, Zhu XX. 2010. LC/MS determination of berberine and palmatin in rats plasma after oral administration of extracts Rhizoma Coptidis and its pharmacokinetics study. Chin J Exp Trad Med. 16:186–189.

Bilan X, Daohua X, Wenshuang C. 2011. Effects of berberine on cancellous and cortical bone in rats induced by glucocorticoid. Chin Pharm Bull. 27:965–970.

Bing L, Wang G, Jie Y, Pan X, Yang Z, Zang L. 2011. Berberine inhibits human hepatoma cell invasion without cytotoxicity in healthy hepatocytes. PLoS One. 6:e21416.

Boberek JM, Stach J, Good L. 2010. Genetic evidence for inhibition of bacterial division protein FtsZ by berberine. PLoS One. 5:e13745.

Cai Y, Xia Q, Luo R, Huang P, Sun T, Shi Y, Jiang W. 2014. modulation of gut microbiota by berberine improves steatohepatitis in high-fat diet-fed BALB/C mice. Arch. Microbiol. 196:97–103.

Chen C, Zhang Y, Huang C. 2010. Berberine inhibits PTP1B activity and attenuates atherosclerosis in ApoE-/- mice. J Agri Food Chem. 59:8021–8027.

Chen HY, Ye XL, Cui XL, He K, Jin YN, Chen Z, Li XG. 2012. Cytotoxicity and antihyperglycemic effect of minor constituents from Rhizoma Coptidis. J Cardiovasc Pharmacother. 21:486–494.

Chang W, Li K, Guan F, Yao F, Yu Y, Zhang M, Hatch GM, Chen L. 2016. Berberine suppresses tumor growth and progression by down-regulating MFG-E8 in colorectal cancer. RSC Adv. 6:30937–30945.

Chen J, Wang F, Liu J, Lee SC, Wang X, Yang H. 2008. Analysis of alkaloids and antihyperglycemic effect of minor constituents from Rhizoma Coptidis exerts an anti-cancer effect on hepatocellular carcinoma by up-regulating miR-122. Biomed Pharmac. 103:1002–1011.

Chakravarthy D, Muñoz AR, Su A, Huang RF, Keppler BR, Chan DE, Halff G, Ghosh R, Kumar AP. 2018. Palmitate suppresses glutamine-mediated interaction between pancreatic cancer and stellate cells through simultaneous inhibition of survivin and COIL1A1. Cancer Lett. 419:103–115.

Chen R, Wu Y, Tian W. 2016. Research progress in chemical constituents of Coptidis rhizome. Chin J Chin Mater Med. 37:1241–1244.

Chen J, Feng M, Kong SZ, Wang ZX, He K, Zou ZY, Hu YR, Ma H, Li XG, Ye XL. 2017. The protective effect of coptisine on experimental atherosclerosis in ApoE/-/- mice is mediated by MAPK/NIK-xB-dependent pathway. Biomed Pharmacother. 93:721–729.

Chen J, Feng M, Kong SZ, Wang ZX, He K, Zou ZY, Hu YR, Ma H, Li XG, Ye XL. 2017. The protective effect of coptisine on experimental atherosclerosis ApoE/-/- mice is mediated by MAPK/NIK-xB-dependent pathway. Biomed Pharmacother. 93:721–729.

Chinese Pharmacopoeia Commission. 2008. Xin yao zhuan zheng biao zhun. Beijing: China Medical Science Press.

Chinese Pharmacopoeia Commission. 2015. Chinese pharmacopoeia. Vol. 1. Beijing: China Medical Science Press.

Choi JS, Kim KH, Ali MY, Jung HJ, Min BS, Choi RJ, Kim GD, Jung HA. 2013. Anti-adipogenic effect of epiberberine is mediated by regulation of the RAP/MEK(1/2)/ERK1/2 and AMPK/akt pathways. Arch Pharm Res. 36:2153–2162.

Choi JS, Kim KH, Ali MY, Min BS, Kim GD, Jung HA. 2014. Coptis chinensis alkaloids exert anti-adipogenic activity on 3T3-L1 adipocytes by downregulating C/EBP-β and PPAR-γ. Fitoterapia. 98:199–208.

Choi UK, Kim MH, Lee NH. 2007. Optimization of antibacterial activity by gold-thread (Coptis Rhizoma Franch) against streptococcus mutans using evolutionary operation-factorial design technique. J Microbiol Biotechnol. 17:1880–1884.

Chu M, Ding R, Chu ZY, Zhang MB, Liu XY, Xie SH, Zhai YJ, Wang YD. 2014. Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4/MD-2 receptor. BMC Complement Altern Med. 14:89–97.

Chuanchong X. 2016. Berberine inhibits macrophages inflammatory depending on sirt1 [Master's thesis]. Nanjing: Nanjing University of Chinese Medicine.

Chueh WH, Lin JY. 2011. Berberine, an isoquinoline alkaloid in herbal plants, protects pancreatic islets and serum lipids in nonobese diabetic mice. J Agric Food Chem. 59:8021–8027.

Cui G, Aissier C, Salie M, Oram DS, Chenge J, Louters LL. 2011. Berberine acutely activates the glucose transport activity of GLUT1. Biochim. 93:1187–1192.

Curcumin. 2010. LC/MS determination of berberine and palmatin in rats plasma after oral administration of extracts Rhizoma Coptidis and its pharmacokinetics study. Chin J Exp Trad Med. 16:186–189.

Dong J. 2003. Lv she bei yao fang. Shanghai: Shanghai science and technology press.
Feng L, Hao Z, Hua H. 2007. The protective effect of cotisine on gastric mucosal injury induced by irritable mice. West Chin J Pharm Sci. 22:713–714.

Flora of China Committee of Chinese Academy of Sciences. 2004. Flora of China. Vol. 27. Beijing: Science Press; p. 593.

Friedemann T, Schumacher U, Tao Y, Leung KM, Schroder S. 2015. Neurpocryptive activity of cotisine from Coptis chinensis (Fisch). Evid Based Complement Alternat Med. 2015:827308–827316.

Friedemann T, Ying Y, Wang W, Kramer ER, Schumacher U, Fei J, Schroder S. 2016. Neurpocryptive effect of cotisine in MPP+ and MPTP-induced Parkinson’s Disease Models. Am J Chinese Med. 44:907–925.

Fujiwara H, Nonaka G, Yagi A, Nishioka I. 1976. Studies on the components of Coptis japonica Makino. I. The structures of coptiside I and II. Chem Pharm Bull. 24:407–413.

Gong Z, Chen Y, Zhang R, Wang Y, Guo Y, Yang Q, Zhang H, Dong Y, Weng X, Gao S, et al. 2014. Pharmacokinetic comparison of berberine in rat plasma after oral administration of berberine hydrochloride in normal and post inflammation irritable bowel syndrome rats. Int J Mol Sci. 15:456–467.

Gu N, Zhang X, Yu H. 2017. Based on sequencing of 16s rRNA gene elaboration of effect of coptis chinensis on intestinal microbial diversity in type 2 diabetes mellitus. Chin Trad Herbal Drugs. 48:3998–4004.

Guo T, Shih-Lung W, Guo X, Li H, Zheng J, Rachel B, Liu M, Pei Y, Xu H, Cai Y. 2016. Berberine ameliorates hepatic steatosis and suppresses liver and adipose tissue inflammation in mice with diet-induced obesity. Sci Rep. 6:22612–22620.

Guo J, Yang SB, Tian TY, Wu YJ, Yan Y, Li L, Xu XN, Gong LL, Qin HL, Fang LH. 2013. Coptisine protects rat heart against myocardial ischemia/reperfusion injury by suppressing myocardial apoptosis and inflammation. Atherosclerosis. 231:384–391.

Guo. 2002. Guo jia zhong cheng yao biao zhun. Beijing: The State Drug Flora of China Committee of Chinese Academy of Sciences. 2004.

Huang Z, Han Z, Ye B, Dai Z, Shan P, Lu Z, Dai K, Wang C, Huang W. 2015. Berberine alleviates cardiac ischemia/reperfusion injury by inhibiting excessive autophagy in cardiomyocytes. Eur J Pharmacol. 762:1–10.

Huang Z, Wang L, Meng S, Wang Y, Chen T, Wang C. 2011. Berberine reduces both MMP-9 and emmin expression through prevention of p38 pathway activation in PMA-induced macrophages. Int J Cardiol. 146:153–158.
Ma, Chen G, Pei YH. 2013. Isolation and identification of chemical constituents from rhizoma of Coptis chinensis and their cytotoxic activities. J Ethnopharmacol. 149(1):1-9.

Ma H, Hu YR, Zou ZY, Feng M, Ye XL, Li XG. 2016. Antihyperglycemia and antihyperlipidemia effect of protoberberine alkaloids from Rhizoma Coptidis in HepG2 cell and diabetic kk-ay mice. Drug Develop Res. 77:163–170.

Ma X, Liu H, Chen G. 2015. Effects of berberine combined with photodynamic on apoptosis of gastric cancer MGC-803 cell. Chin J Clin Pharm Ther. 19(9):609–614.

Ma BL, Ma YM. 2013. Pharmacokinetic properties, potential herb-drug interactions and acute toxicity of oral Rhizoma Coptidis alkaloids. Exp Opin Drug Metab Toxicol. 9:51–61.

Maiti M, Nandi R, Chaudhuri K. 1982. Sanguinarine: a monofunctional inhibitor of NO synthase in the rabbit aorta. J Pharmacol Exp Ther. 20:961–966.

Min ZD, Murata H, Mizuno M, Kojima H, Tanaka T, Iinuma M, Kimura R. 2009. Identification of the toxic constituents in Rhizoma Coptidis. J Ethnopharmacol. 128:357–364.

Ma B, Zhi L, Zang X, Chen Y, Li D, Wang Y. 2013. Coptis chinensis inflorescence and its main alkaloids protect against ultraviolet-B-induced oxidative damage. J Funct Foods. 5:1663–1672.

Maiti M, Nandi R, Chaudhuri K. 1982. Sanguinarine: a monofunctional inhibitor of NO synthase in the rabbit aorta. J Pharmacol Exp Ther. 20:961–966.

Mei J. 2008. Study on processing technology and quality control of Coptidis Rhizoma [Dissertation]. Wuhan: Hubei College of Traditional Chinese Medicine.

Mei L. 2011. Analysis of 37 cases of frequent atrial premature beats in the treatment of berberine. Chin J Misdiagn. 11:4467–4467.

Mendis S, Puska P, Norrving B. 2011. Global atlas on cardiovascular disease prevention and control. WHO, World Heart Federation and World Stroke Organization.

Meng L, Shu X, Xu H, Zhang C, Yang L, Li Z, Ji G. 2016. Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds. J Transl Med. 14:237–248.

Meng F, Wang L, Zhang J, Yin Z, Zhang Q, Ye W. 2013. Non-alkaloid chemical constituents from the rhizome of Coptis teeta. J Chin Pharm Univ. 44:307–310.

Min ZD, Murata H, Mizia M, Kojima H, Tanaka T, Inuma M, Kimura R. 1987. Phenolic constituents from seeds of Coptis japonica var. Dissecta. Phytochemistry. 26:2071–2074.

Ming C, Zhang M, Liu Y, Kang J, Chu Z, Yin K, Ding L, Ran D, Xiao R, Yin Y. 2016. Role of berberine in the treatment of methicillin-resistant Staphylococcus aureus infections. Sci Rep. 6:24748–24756.

Mishan MA, Ahmadiankia N, Matin MM, Heiri-Tabasi A, Shahriyari M, Sun Y, Xia M, Yan H, Han Y, Zhang F, Hu Z, Cui A, Ma F, Liu Z, Gong Q. 2017. Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21. Br J Pharmacol. 12:2139–2148.

Salehi S, Fitzm TM. 2011. Berberine possesses murscinar agonist-like properties in cultured rodent cardiomyocytes. Pharm Res. 35:335–340.

Sharma M, Baburin I, Hering S, Hamburger M. 2011. Herg channel inhibitors in extracts of Coptidis Rhizoma. Planta Med. 77:692–697.

Shi Y, Hu F. 2014. The global implications of diabetes and cancer. Lancet. 383:1947–1948.

Shen J. 2006. The resource utilization and research progress of Coptidis Rhizoma. J Med Math. 22:1038–1039.

Shen N, Huan Y, Shen ZF. 2012. Berberine inhibits mouse insulin gene promoter through activation of amp activated protein kinase and may exert beneficial effect on pancreatic β-cell. Eur J Pharmacol. 694:120–126.

Zheng M, Sun Q, Wang H. 1993. Study on the pharmacokinetics of berberine hydrochloride in beagle dog vein and oral administration. Chin Pharmacol Bull. 9:64–67.

Sheng M, Sun Q, Wang H. 1993. Study on the pharmacokinetics of berberine hydrochloride in beagle dog vein and oral administration. Chin Pharmacol Bull. 9:64–67.

Sheng M, Sun Q, Wang H. 1993. Study on the pharmacokinetics of berberine hydrochloride in beagle dog vein and oral administration. Chin Pharmacol Bull. 9:64–67.

Sun S, Wang K, Lei H, Li L, Tu M, Zeng S, Zhou H, Jiang H. 2014. Downregulation of cellular c-Jun N-terminal protein kinase and NF-kappa B activation by berberine may result in inhibition of herpes simplex virus replication. Antimicrob Agents Chemother. 58:5068–5078.

Steenbergen C, Frangogiannis NG. 2012. Chapter 36 - Ischemic heart disease. In: Joseph A. Hill, Eric N. Olson, editors. New York (NY): Muscle, Academic Press; p. 495–521.

Su G, Wang H, Gao Y, Chen G, Pei Y, Bai J. 2017. 1H-NMR-based metabolomics of the protective effect of Coptis chinensis and berberine on cinnabar-induced hepatotoxicity and nephrotoxicity in rats. Molecules. 22:4567.

Sun W, Wang H, Cang Z, Zhu C, Zhao L, Nie X, Cheng J, Xia F, Zhai H, Lu Y. 2016. Modulation of microbiota-gut-brain axis by berberine resulting in improved metabolic status in high-fat diet-fed rats. Obesity Facts. 9:365–378.

Sun S, Wang K, Lei H, Li L, Tu M, Zeng S, Zhou H, Jiang H. 2014. Inhibition of organic cation transporter 2 and 3 may be involved in the mechanism of the antidepressant-like action of berberine. Progr Neuropsychopharmacol Biol Psychiatry. 49:1–6.

Sun Y, Xia M, Yan H, Han Y, Zhang F, Hu Z, Cui A, Ma F, Liu Z, Gong Q. 2017. Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibrolast growth factor 21. Br J Pharmacol. 12:2139–2148.

Tabas I, Garcia-Cardenas G, Owens GK. 2015. Recent insights into the cellular biology of atherosclerosis. J Cell Biol. 209:13–22.

Tan HY, Wang N, Tiao SW, Zhang Z, Feng Y. 2014. Suppression of vascular endothelial growth factor via inactivation of eukaryotic elongation factor 2 by alkaloids in Coptidis Rhizome in hepatocellular carcinoma. Integr Cancer Ther. 13:425–434.

Tang S. 2011. Classified Materia Medica from historical classics for emergency. Beijing: China Medical Press.

Tang LC, Wei W, Chen LM, Liu S. 2006. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol. 108:109–115.

Tang F, Wang D, Duan C, Huang D, Wu Y, Chen Y, Wang W, Xie C, Meng J, Wang L, et al. 2009. Berberine inhibits metastasis of nasopharyngeal carcinoma S-8P cells by targeting Rho kinase-mediated Erzrin phosphorylation at Thrineine 567. J Biol Chem. 284:27456–27466.

Tan L, Li C, Chen H, Mo Z, Zhou J, Liu Y, Ma Z, Xu Y, Yang X, Xie J, et al. 2017. Epiberberine, a natural protoberberine alkaloid, inhibits urease
of *Helicobacter pylori* and jack bean: Susceptibility and mechanism. Eur J Pharm Sci. 110:77–86.

Ti H. 2017. Effects of Rhizoma Coptidis decoction on intestinal flora and GPR43 pathway GLP-1 and PYY in SD rats with metabolic syndrome [Master’s thesis]. Beijing: Beijing University of Chinese Medicine.

Tjong Y, Ip S, Lao L, Fong HHS, Sung JYJ, Berman B, Che C. 2011. Analgesic effect of *Coptis chinensis* rhizomes (Coptidis Rhizoma) extract on rat model of irritable bowel syndrome. J Ethnopharmacol. 135:754–761.

Tomita M, Kura S. 1956. Isolation of magnoflorine from *Coptis japonica* Makino. J Pharm Soc Jap. 76:1423–1426.

Tsang CM, Cheung KC, Cheung YC, Man K, Lui VW, Fung Y, Tsao SW. 2015. Berberine suppresses ID-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma. Biochim Biophys Acta. 1852:541–551.

Varghese FS, Thaa B, Amrun SN, Simarmata D, Rausalu K, Nyman TA, Wang Y, Wang Q, Zhang L, Ke Z, Zhao Y, Wang D, Chen H, Jiang X, Gu TSang CM, Cheung KC, Cheung YC, Man K, Lui VW, Fung Y, Tsao SW. 2015. Berberine suppresses ID-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma. Biochim Biophys Acta. 1852:541–551.

Wang G. 1991. *Bo ji fang*. Beijing: Zhonghua Book Company.

Wang W. 2016. A review on pharmacologic effects of effective ingredients in huanglian. Clin J Chin Med. 8:147–148.

Wang N, Feng Y, Lau EP, Tsang C, Ching Y, Man K, Tong Y, Nagamatsu T, Su W, Tsao S. 2010. F-actin reorganization and inactivation of Rho signaling pathway involved in the inhibitory effect of Coptidis Rhizoma on hepatoma cell migration. Int J Cancer. 9:354–364.

Wang Y, Huang Y, Lam KSL, Li Y, Wong WT, Ye H, Lau CW, Vanhoutte PM, Xu A. 2009. Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase signaling. J Virol. 90:9743–9757.

Ye L. 2007. The study of berberine inhibition of Cyclin D1 related signaling. Chin J Trad Med Intern Med. 24:1441–1444.

Ye L, Liang S, Guo C, Yu X, Zhao J, Zhang H, Shang W. 2016. Inhibition of M1 macrophage activation in adipose tissue by berberine improves insulin resistance. Life Sci. 166:82–91.

Yi J, Ye X, Wang D, He K, Yang Y, Liu X, Li X. 2013. Safety evaluation of main alkaloids from Rhizoma Coptidis. J Ethnopharmacol. 145:303–310.

Yi T, Zhuang L, Song G, Zhang B, Li G, Hu T. 2015. AKT signaling is associated with the berberine-induced apoptosis of human gastric cancer cells. Cell Death Dis. 6:532–533.

Yin J, Hu R, Chen M, Tang J, Li F, Yang Y, Chen J. 2002. Effects of berberine on glucose metabolism in *vitro*. Metabolism. 51:1439–1443.
Yong Y, Baoshun Z, Chunya C. 2011. Cardiovascular pharmacological activ-
ity of berberine. Chin Trad Pat Med. 33:867–869.
Yong Y, Xiaoli Y, Xuegang L. 2007. Antimicrobial effect of four alkaloids
from Coptidis Rhizome. Lishizhen Med Mater Med Res. 18:3013–3014.
Yoshikawa K, Hiroshi Kinoshita A, Arihara S. 1997a. Woorenol, a novel ses-
quineolignan with a unique spiro skeleton, from the rhizomes of Coptis
japonica var. J Nat Prod. 60:511–513.
Yoshikawa K, Hiroshi Kinoshita A, Arihara S. 1997b. Non-basic components
of Coptis Rhizoma: Four new hemiterpenoid glucosides, two new phenyl-
propanoid glucosides and a new flavonoid glycoside from Coptis japonica
var. dissecta. Nat Med. 51:244–248.
Yoshikawa K, Hiroshi Kinoshita A, Kan Y, Arihara S. 1995. Neolignans and
phenylpropanoids from the rhizomes of Coptis japonica var. Dissecta.
Chem Pharm Bull. 43:578–581.
Yu D, Fu S, Cao Z, Bao M, Zhang G, Fan Y, Liu W, Zhou Q. 2014. Unraveling
the novel anti-osteosarcoma function of cotisine and its mechanisms.
Toxicol Lett. 226:328–336.
Yu L, Li Q, Yu B, Yang Y, Jin Z, Duan W, Zhao G, Zhai M, Liu L, Yi D, et al. 2016. Berberine attenuates myocardial ischemia/reperfusion injury
by reducing oxidative stress and inflammation response: Role of silent
information regulator 1. Oxidative Med Cell Long. 2016:1689602–1689617.
Yu L, Li F, Zhao G, Yang Y, Jin Z, Zhai M, Yu W, Zhao I, Chen W, Duan W. 2015. Protective effect of berberine against myocardial ischemia reper-
fusion injury: Role of notch1/hes1-p1tn-akt1 signaling. Apoptosis. 20:796–810.
Yu L, Liu L, Wang X, Liu X, Xie L, Wang G. 2010. Modulation of gluco-
lagon-like peptide-1 release by berberine: in vivo and in vitro studies.
Biochem Pharmacol. 79:1000–1006.
Yu S, Pang X, Deng Y, Liu L, Liang Y, Liu X, Xie L, Wang G, Wang X.
2007. A sensitive and specific liquid chromatography mass spectrometry
method for simultaneous determination of berberine, palmatine, cotisine,
epiberberine and jatrohrrhizine from Coptidis Rhizoma in rat plasma. Int J
Mass Spectrom. 268:30–37.
Yu S, Yu Y, Liu L, Wang X, Lu s, Liang Y, Liu X, Xie L, Wang G. 2010.
Increased plasma exposures of five protoberberine alkaloids from Coptidis
Rhizoma in streptoztocin-induced diabetic rats is P-GP involved? Planta
Med. 76:876–881.
Yu S, Yu Y, Lu S, Liu L, Liu X. 2008. Pharmacokinetics of berberine, palma-
tine, cotisine, epiberberine and jatrohrrhizine from Coptidis Rhizoma in
diabetic rats. J Chin Pharm Univ. 39:526–529.
Yu C, Zhang H, Pan J, Hong Y, Ren J, Zhu D, Xiu H. 2000. Determination
and preliminary studies of metabolism of berberine in human urine after
oral administration. Chin J Clin Pharmacol. 1:36–39.
Yu R, Zhang ZQ, Wang B, Jiang HX, Cheng L, Shen LM. 2014. Berberine-
induced apoptotic and autophagic death of HepG2 cells requires AMPK
activation. Cancer Cell Int. 14:1–8.
Yuan X, Wang J, Tang X, Li Y, Xie P, Gao X. 2015. Berberine ameliorates
nonalcoholic fatty liver disease by a global modulation of hepatic mRNA
and lncRNA expression profiles. J Transl Med. 13:24.
Zhang J. 1996. Jingyue’s complete works. Shanghai: Shanghai Scientific &
Technical Publishers.
Zhang B, Cao A, Zhou J, Hu Z, Wu D. 2012. Effect of jatrohrrhizine on
delayed gastrointestinal transit in rat postoperative ileus. J Pharm
Pharmacol. 64:413–419.
Zhang C, Jing P, Li N. 2013. Berberine inhibits the proliferation and induces
apoptosis of human ovarian cancer SKOV3 cells. Basic Clin Med. 33:
225–226.
Zhang J, Tang H, Deng R, Wang N, Zhang Y, Wang Y, Liu Y, Li F, Wang X,
Zhou I. 2015. Berberine suppresses adipocyte differentiation via decreas-
ing CREB transcriptional activity. PLoS One. 10:e0125667–e0125675.
Zhang Q, Xiao X, Li M, Li W, Yu M, Zhang H, Fan P, Wang Z, Zheng J. 2014.
Berberine moderates glucose metabolism through the GNRH-GLP-1
and MAPK pathways in the intestine. BMC Complement Altern Med. 14:
188–197.
Zhang T, Yang S, Du J. 2014. Protective effects of berberine on iso-
proterenol-induced acute myocardial ischemia in rats through regulating
HMGBl-TLR4 axis. Evid Based Complement Alternat Med. 2014:1–8.
Zhang Z, Li B, Meng X, Yao S, Jin L, Yang J, Wang J, Zhang H, Zhang Z,
Cai D, et al. 2016. Berberine prevents progression from hepatic steatosis
to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress.
Sci Rep. 6:20848–20860.
ZHANG W, Xu Yc, GUO Fj, MENG Y, Li ML. 2008. Anti-diabetic effects
of cinnamaldehyde and berberine and their impacts on retinol-binding pro-	ein 4 expression in rats with type 2 diabetes mellitus. Chin Med J. 121:
2124–2128.
Zhao Y, Adjei AA. 2015. Targeting angiogenesis in cancer therapy: moving
beyond vascular endothelial growth factor. Oncologist. 20:660–673.
Zhao M, Xian YF, Ip SP, Fong HH, Che CT. 2010. A new and weakly anti-
spasmodic protobbererine alkaloid from Rhizoma Coptidis. Phytother Res.
24:1414–1416.
Zhou GL, Yu LM, Gao Wl, Duan WS, Jiang B, Liu Xd, Zhang B, Liu Zh, Zhai
Me, Jin Zx, et al. 2016. Berberine protects rat heart from ischemia/reperfu-
sion injury via activating JAK2/STAT3 signaling and attenuating endoplasmic
reticulum stress. Acta Pharmacol Sin. 37:354–367.
Zhong. 1991. Zhong yao cheng fang zhi ji. Vol 4. Beijing: Pharmacopoeia
Committee of the People’s Republic of China Ministry of Health.
Zhong. 1998. Zhong yao cheng fang zhi ji. Vol 17. Beijing: Pharmacopoeia
Committee of the People’s Republic of China Ministry of Health.
Zhou L, Yu Yang, Li G, Huang J, Liu Y, Zhang Q, Tang Q, Hu C, Zhang R.
2018. Cotisine induces apoptosis in human hepatoma cells through activat-
ing 67-kDa Lammin receptor/cGMP signaling. Front Pharmacol. 9:517–533.
Zhou JY, Zhou SW. 2011. Protective effect of berberine on antioxidant
enzymes and positive transcription elongation factor b expression in dia-
betic rat liver. Fitoradopa. 82:184–189.
Zou X, Li H, Shi Z, Gao S, Wei S, Li K, Wang J, Li J, Wang R, Gong M,
et al. 2017. Inhibition activity of a traditional chinese herbal formula
Huang-Lian-Jie-Du-Tang and its major components found in its plasma
profile on neuraminidase-1. Sci Rep. 7:15549–15558.
Zhu DX. 2012. Danxi’s mastery of medicine. Beijing: China Medical Science
Press.
Zhu G. 2015. Lei zheng huo ren shu. Tianjin: Tianjin Scientific & Technical
Press.
Zhu T, Li LL, Xiao GF, Luo QZ, Liu QZ, Yao KT, Xiao GH. 2015. Berberine
increases doxorubicin sensitivity by suppressing STAT3 in lung cancer.
Am J Chinese Med. 43:1487–1502.
Zhu Q, Li Y. 2016. Berberine attenuates myocardial ischemia reperfusion
injury by suppressing the activation of PI3K/AKT signaling. Exp Ther
Med. 11:978–984.
Zhu Y, Ma N, Li GX, Tian L, Bao YH, Hao B. 2014. Berberine induces apop-
tosis and DNA damage in MG-63 human osteosarcoma cells. Mol Med
Rep. 10:1734–1738.
Zou ZY, Hu YR, Ma H, Feng M, Li XG, Ye XL. 2016. Epiberberine reduces
serum cholesterol in diet-induced dyslipidemia syrian golden hamsters
via network pathways involving cholesterol metabolism. Eur J Pharmacol.
774:1–9.
Zuo F, Nakamura N, Akao T, Hattori M. 2006. Pharmacokinetics of berber-
ine and its main metabolites in conventional and pseudo germ-free rats
determined by liquid chromatography/ion trap mass spectrometry. Drug
Metab Dispos. 34:2064–2072.